{"entity":{"id":"2023","kind":"year","name":"2023 in oncology","aka":["2023"],"tldr":"Everything OnCo dates to 2023: 719 entries, 176 papers, 132 papers listed on people's pages, 126 trials reported and 123 landmarks. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"719 dated entries in OnCo fall in 2023: 176 papers, 132 papers listed on people's pages, 126 trials reported, 123 landmarks, 66 approvals, 42 regulatory events, 20 financing rounds, 16 technologies, 13 guideline changes, 2 companies founded, 2 expected dates and 1 law or regulation.\n\nOf those, 29 to the day, 27 to the month and 663 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2022","2024"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2023,"events":[{"group":"approval","date":"2023","precision":"year","title":"Adebrelimab approved in China","note":"First-line extensive-stage small cell lung cancer with carboplatin and etoposide (CAPSTONE-1)","from":"adebrelimab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Belzutifan approved in US","note":"Advanced RCC after PD-1/PD-L1 and VEGF-TKI","from":"belzutifan","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Bevacizumab approved in US","note":"Refractory mCRC with trifluridine/tipiracil (SUNLIGHT)","from":"bevacizumab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Binimetinib approved in US","note":"BRAF V600E metastatic NSCLC with encorafenib","from":"binimetinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Camrelizumab + rivoceranib approved in China","note":"First-line unresectable HCC","from":"camrelizumab-rivoceranib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Capivasertib approved in US","note":"HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant","from":"capivasertib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Crisantaspase (recombinant Erwinia asparaginase) approved in EU","note":"ALL and lymphoblastic lymphoma, in a multi-agent regimen, after hypersensitivity or silent inactivation to E. coli-derived asparaginase (adults and children from 1 month).","from":"crisantaspase","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Dabrafenib + trametinib approved in England (NICE)","note":"BRAF V600 mutation-positive advanced non-small-cell lung cancer, first line only. TA898, published 14 June 2023, recommends the combination only as first-line treatment of advanced...","from":"dabrafenib-trametinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Dalpiciclib approved in China","note":"First-line HR-positive, HER2-negative advanced breast cancer with an aromatase inhibitor (DAWNA-2)","from":"dalpiciclib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Decitabine + cedazuridine (oral) approved in EU","note":"EU brand Inaqovi","from":"decitabine-cedazuridine","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Efbemalenograstim alfa approved in US","note":"Decrease in febrile neutropenia in adults with non-myeloid malignancies on myelosuppressive chemotherapy","from":"efbemalenograstim-alfa","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Eflornithine (DFMO) approved in US","note":"Maintenance to reduce relapse risk in high-risk neuroblastoma after ≥PR to prior therapy including anti-GD2","from":"eflornithine","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Elacestrant approved in US","note":"ESR1-mutant ER+/HER2- advanced breast cancer after ≥1 endocrine therapy","from":"elacestrant","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Elranatamab approved in US","note":"Relapsed/refractory myeloma after ≥4 lines (accelerated)","from":"elranatamab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Enfortumab vedotin approved in US","note":"First-line advanced urothelial cancer with pembrolizumab","from":"enfortumab-vedotin","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Enzalutamide approved in US","note":"High-risk biochemical recurrence (EMBARK)","from":"enzalutamide","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Epcoritamab approved in EU","note":"EU brand Tepkinly. Conditional marketing authorisation","from":"epcoritamab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Epcoritamab approved in US","note":"Relapsed/refractory DLBCL or high-grade B-cell lymphoma after ≥2 lines (accelerated)","from":"epcoritamab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Equecabtagene autoleucel approved in China","note":"Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent","from":"equecabtagene-autoleucel","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Flotufolastat F-18 approved in US","note":"PSMA PET in prostate cancer","from":"flotufolastat","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Fruquintinib approved in US","note":"Refractory mCRC after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF, and anti-EGFR if appropriate","from":"fruquintinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Futibatinib approved in EU","note":"Same","from":"futibatinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Glofitamab approved in US","note":"Relapsed/refractory DLBCL after ≥2 lines (accelerated)","from":"glofitamab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Glumetinib approved in CN","note":"Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","from":"glumetinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Guardant360 CDx approved in US","note":"Companion diagnostic for elacestrant (ESR1 mutation) in ER+/HER2- advanced breast cancer","from":"guardant360-cdx","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Inaticabtagene autoleucel approved in China","note":"Adult relapsed or refractory CD19-positive B-cell acute lymphoblastic leukaemia","from":"inaticabtagene-autoleucel","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Iruplinalkib approved in CN","note":"ALK-positive non-small-cell lung cancer after crizotinib; first line from 2024","from":"iruplinalkib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Ivosidenib approved in US","note":"Relapsed/refractory IDH1-mutated MDS","from":"ivosidenib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Luspatercept approved in US","note":"First-line anaemia in ESA-naive lower-risk MDS","from":"luspatercept","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Melphalan (including hepatic delivery system) approved in US","note":"Uveal melanoma with unresectable hepatic metastases via hepatic delivery system (Hepzato Kit)","from":"melphalan","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Melphalan hepatic delivery system approved in US","note":"Uveal melanoma with unresectable hepatic metastases affecting less than half the liver and no or limited extrahepatic disease","from":"hepzato","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Momelotinib approved in US","note":"Intermediate/high-risk myelofibrosis with anaemia","from":"momelotinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Motixafortide approved in US","note":"With filgrastim, to mobilise haematopoietic stem cells for collection and autologous transplantation in multiple myeloma","from":"motixafortide","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Nirogacestat approved in US","note":"Progressing desmoid tumours requiring systemic treatment","from":"nirogacestat","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Nivolumab approved in England (NICE)","note":"Neoadjuvant treatment of resectable non-small-cell lung cancer (4 cm or more, or node positive), with chemotherapy. TA876, published 22 March 2023 (CheckMate 816).","from":"nivolumab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Olaparib approved in UK","note":"Adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapy; NICE TA886 (10 May 2023) recommends within the marketing authorisation...","from":"olaparib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Omidubicel approved in US","note":"Adults and children aged 12 and over with haematologic malignancies undergoing umbilical cord blood transplantation after myeloablative conditioning, to reduce time to neutrophil r...","from":"omidubicel","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Orelabrutinib approved in China","note":"Relapsed or refractory marginal zone lymphoma","from":"orelabrutinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Previously treated MSI-high or dMMR endometrial, biliary, colorectal, gastric or small intestine cancer.","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Pembrolizumab approved in UK","note":"Mismatch repair deficient or MSI-high tumours: NICE TA914 (20 September 2023) covers previously treated endometrial, gastric, small intestine, biliary and colorectal cancer and doe...","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Pembrolizumab approved in US","note":"Locally advanced unresectable or metastatic biliary tract cancer (gallbladder cancer included) with gemcitabine and cisplatin (KEYNOTE-966).","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Piflufolastat F-18 / Pylarify TruVu approved in EU","note":"EU brand Pylclari (Curium)","from":"pylarify","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Pirtobrutinib approved in US","note":"Relapsed MCL after BTK inhibitor (accelerated, January); CLL/SLL after BTK and BCL-2 inhibitors (accelerated, December)","from":"pirtobrutinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Polatuzumab vedotin approved in US","note":"Untreated DLBCL, IPI ≥2, with R-CHP (Pola-R-CHP)","from":"polatuzumab-vedotin","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Quizartinib approved in US","note":"Newly diagnosed FLT3-ITD AML with 7+3, consolidation, and maintenance","from":"quizartinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Regorafenib approved in England (NICE)","note":"Metastatic colorectal cancer after previous treatment or when those treatments are unsuitable.","from":"regorafenib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Repotrectinib approved in US","note":"ROS1+ locally advanced or metastatic NSCLC","from":"repotrectinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Retifanlimab approved in US","note":"Metastatic or recurrent locally advanced Merkel cell carcinoma","from":"retifanlimab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Rivoceranib (apatinib) approved in China","note":"First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)","from":"rivoceranib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Sacituzumab govitecan approved in US","note":"HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies","from":"sacituzumab-govitecan","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Selpercatinib approved in England (NICE)","note":"Untreated RET fusion-positive advanced non-small-cell lung cancer. TA911, published 26 July 2023, recommends selpercatinib with managed access only, under a managed access agreemen...","from":"selpercatinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Sintilimab approved in China","note":"First-line gastric or gastro-oesophageal junction adenocarcinoma with chemotherapy (ORIENT-16)","from":"sintilimab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Sodium thiosulfate (otoprotectant) approved in EU","note":"Same","from":"sodium-thiosulfate","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Sunvozertinib approved in CN","note":"EGFR exon 20 insertion NSCLC after platinum","from":"sunvozertinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Talazoparib approved in US","note":"HRR-mutant mCRPC with enzalutamide","from":"talazoparib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Talicabtagene autoleucel approved in IN","note":"Relapsed or refractory B-cell lymphoma and B-cell acute lymphoblastic leukaemia. DCGI market authorisation; first CAR-T approved in India","from":"talicabtagene-autoleucel","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Talquetamab approved in US","note":"Relapsed/refractory myeloma after ≥4 lines (accelerated)","from":"talquetamab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Tempus xT CDx approved in US","note":"Companion diagnostic for cetuximab and panitumumab (KRAS/NRAS wild-type colorectal cancer) with tumour-profiling claims","from":"tempus-xt-cdx","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Toripalimab approved in US","note":"Recurrent/metastatic nasopharyngeal carcinoma, first line with chemotherapy and later lines","from":"toripalimab","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Trastuzumab deruxtecan approved in EU","note":"Unresectable or metastatic HER2-low breast cancer after chemotherapy in the metastatic setting or recurrence within 6 months of adjuvant chemotherapy (DESTINY-Breast04), hormone-re...","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Trifluridine/tipiracil approved in US","note":"Refractory mCRC with bevacizumab","from":"trifluridine-tipiracil","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Tucatinib approved in US","note":"HER2+ RAS-wild-type mCRC with trastuzumab","from":"tucatinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Tucatinib approved in US","note":"HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer that has progressed after fluoropyrimidine, oxaliplatin and irinotecan, with trastuzumab.","from":"tucatinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Vebreltinib approved in CN","note":"Locally advanced or metastatic non-small cell lung cancer with MET exon 14 skipping","from":"vebreltinib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Vorolanib approved in CN","note":"Advanced renal cell carcinoma after a prior tyrosine kinase inhibitor, with everolimus (June 2023)","from":"vorolanib","refs":[]},{"group":"approval","date":"2023","precision":"year","title":"Zanubrutinib approved in US","note":"CLL/SLL, all lines (SEQUOIA, ALPINE)","from":"zanubrutinib","refs":[]},{"group":"company","date":"2023","precision":"year","title":"NEC Bio founded","note":"Schiphol","from":"nec-bio","refs":[]},{"group":"company","date":"2023","precision":"year","title":"Noetik founded","note":"South San Francisco, CA","from":"noetik","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Abdera Therapeutics: Series B","note":"$110m. Led by venBio Partners; the company's launch release reports USD 142 million in combined Series A and B financing","from":"abdera-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Adela: Series A","note":"$48m. Round name not given in the release (listed as Series A1 extension on the company news page); existing investors plus new investor Labcorp; cumulative funding $108 million.","from":"adela","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"ARTBIO: Series A","note":"$90m","from":"artbio","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"CARGO Therapeutics: IPO","note":"$281m. 18,750,000 shares at $15.00; Nasdaq CRGX","from":"cargo-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Carrum Health: Series B","note":"$45m. Led by OMERS Growth Equity","from":"carrum-health","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Emergence Therapeutics: Acquisition","note":"Deal terms not disclosed; founding investor Heidelberg Pharma expected about USD 7 million for its stake plus up to USD 5 million in milestones","from":"emergence-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Enliven Therapeutics: Crossover","note":"$165m. 165 million US dollar private placement closed concurrently with the reverse merger into Imara (Nasdaq: ELVN) on 23 February 2023","from":"enliven-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Geneos Therapeutics: Series A","note":"$5m. Series A3","from":"geneos-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Haystack Oncology: Acquisition","note":"$392m. Quest 10-K: all-cash transaction for $392 million net of cash acquired, comprising $304 million cash and contingent consideration initially estimated at $88 million; up to $...","from":"haystack-oncology","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Ibex Medical Analytics: Series C","note":"$55m. Led by 83North, September 2023; cumulative funding over $100 million.","from":"ibex-medical-analytics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"K36 Therapeutics: Series B","note":"$70m. Led by Nextech Invest with participation from Bristol Myers Squibb and existing investors","from":"k36-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Mablink Bioscience: Acquisition","note":"Agreement announced 18 October 2023; terms not disclosed","from":"mablink-bioscience","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Mariana Oncology: Series B","note":"$175m","from":"mariana-oncology","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Neogene Therapeutics: Acquisition","note":"$320m. Initial payment of $200 million on completion (16 January 2023) plus up to $120 million in contingent milestone and non-contingent consideration; total up to $320 million","from":"neogene-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Nimbus Therapeutics: Crossover","note":"$210m. Described by STAT as a private financing round led by GV with SR One and Atlas Venture; no series letter given","from":"nimbus-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Noetik: Seed","note":"$14m. Led by DCVC","from":"noetik","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Onc.AI: Series A","note":"$25m. Company page dated January 2023; investors not named on the page","from":"onc-ai","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"POINT Biopharma: Acquisition","note":"$1.4bn. Cash tender offer at USD 12.50 per share, an aggregate of approximately USD 1.4 billion, under a merger agreement dated 2 October 2023; completion reported in an 8-K filed...","from":"point-biopharma","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Tmunity Therapeutics: Acquisition","note":"Completed in the first quarter of 2023; Gilead reported acquired IPR&D of $481 million for the quarter driven primarily by Tmunity plus Arcellx and Nurix payments, so the Tmunity p...","from":"tmunity-therapeutics","refs":[]},{"group":"funding","date":"2023","precision":"year","title":"Universal DX: Series B","note":"$70m. Initial closing of approximately $70 million with investors including Quest Diagnostics, announced 20 November 2023.","from":"universal-dx","refs":[]},{"group":"history","date":"2023","precision":"year","title":"ADIUVO: no benefit from adjuvant mitotane in low-risk resected disease","note":"Localised adrenocortical carcinoma (ENSAT stage I to III, resectable)","from":"localised-adrenocortical-carcinoma","refs":["mitotane"]},{"group":"history","date":"2023","precision":"year","title":"ADIUVO: no benefit of adjuvant mitotane in low-risk disease","note":"Adrenocortical carcinoma","from":"adrenocortical","refs":["mitotane"]},{"group":"history","date":"2023","precision":"year","title":"ADMEC-O: the first randomised adjuvant signal","note":"Merkel cell carcinoma. 179 patients randomised 2 to 1 to a year of nivolumab or observation; disease-free survival 84 against 73 per cent at 24 months, hazard ratio 0.58 with a con...","from":"merkel-cell-carcinoma","refs":["admec-o"]},{"group":"history","date":"2023","precision":"year","title":"Air pollution gets a mechanism, and first-line treatment is intensified","note":"Lung cancer (all types). PM2.5 was shown to promote rather than initiate EGFR-driven lung cancer, with oncogenic EGFR mutations in 18 percent of histologically normal lungs; FLAURA...","from":"lung-cancer","refs":["paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","paper-heymach-aegean-perioperative-durvalumab-nejm-2023","paper-dellphi-301-nejm-2023"]},{"group":"history","date":"2023","precision":"year","title":"ASCO and CAP HER2 testing update recognises HER2-low","note":"HER2-low and HER2-ultralow metastatic breast cancer","from":"her2-low-metastatic-breast-cancer","refs":[]},{"group":"history","date":"2023","precision":"year","title":"Atezolizumab approved by the FDA, the first drug for the disease","note":"Alveolar soft part sarcoma","from":"alveolar-soft-part-sarcoma","refs":["atezolizumab"]},{"group":"history","date":"2023","precision":"year","title":"Autogene cevumeran phase 1: personalised mRNA vaccine after surgery raises T cells that track with staying recurrence-free","note":"Resectable pancreatic ductal adenocarcinoma","from":"resectable-pdac","refs":["autogene-cevumeran","vinod-balachandran","paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023"]},{"group":"history","date":"2023","precision":"year","title":"Avapritinib approved for indolent SM","note":"Systemic mastocytosis. PIONEER; FDA approval May 2023, the first therapy for the indolent form.","from":"systemic-mastocytosis","refs":["avapritinib"]},{"group":"history","date":"2023","precision":"year","title":"Bispecific antibodies approved","note":"Non-Hodgkin lymphoma (all types). Glofitamab and epcoritamab, off-the-shelf CD20 x CD3 antibodies, approved for relapsed large B-cell lymphoma.","from":"non-hodgkin-lymphoma","refs":["glofitamab","epcoritamab"]},{"group":"history","date":"2023","precision":"year","title":"Blinatumomab after induction: two-year disease-free survival 82 percent in the Interfant pilot","note":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","from":"all-infant","refs":["blinatumomab"]},{"group":"history","date":"2023","precision":"year","title":"Bomedemstat enters phase 3","note":"Essential thrombocythaemia (ET). Merck starts the Shorespan-007 trial against hydroxyurea in high-risk ET.","from":"essential-thrombocythaemia","refs":["bomedemstat"]},{"group":"history","date":"2023","precision":"year","title":"c-TRAK TN: acting on ctDNA came too late","note":"Triple-negative breast cancer (TNBC). UK trial, 161 women under surveillance; 27 percent ctDNA-positive by a year, 72 percent of them already metastatic on staging; none of five gi...","from":"tnbc","refs":["paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","ctdna","idea-tnbc-ctdna-guided-adjuvant-decisions"]},{"group":"history","date":"2023","precision":"year","title":"CARTITUDE-4 and KarMMa-3 move CAR-T earlier; elranatamab and talquetamab approved","note":"Multiple myeloma","from":"multiple-myeloma","refs":["cartitude-4","karmma-3","elranatamab","talquetamab"]},{"group":"history","date":"2023","precision":"year","title":"CheckMate 76K: adjuvant nivolumab approved for stage IIB and IIC","note":"Stage IIB and IIC melanoma","from":"stage-ii-melanoma","refs":["nct04099251","nivolumab"]},{"group":"history","date":"2023","precision":"year","title":"CHONQUER phase 3 trial of ivosidenib opens","note":"Chondrosarcoma","from":"chondrosarcoma","refs":["nct06127407"]},{"group":"history","date":"2023","precision":"year","title":"CLL13: venetoclax-obinutuzumab beats chemoimmunotherapy in fit patients","note":"Chronic lymphocytic leukaemia, first treatment","from":"cll-treatment-naive","refs":["cll13-gaia"]},{"group":"history","date":"2023","precision":"year","title":"CodeBreaK 100 pancreatic cohort (sotorasib) and KRYSTAL-1 (adagrasib) report activity in previously treated pancreatic cancer","note":"KRAS G12C-mutant pancreatic ductal adenocarcinoma","from":"kras-g12c-pdac","refs":["sotorasib","adagrasib","tanios-bekaii-saab"]},{"group":"history","date":"2023","precision":"year","title":"CodeBreaK 200: sotorasib beats docetaxel on progression-free but not overall survival","note":"KRAS G12C-mutant non-small-cell lung cancer","from":"kras-g12c-nsclc","refs":["codebreak-200","sotorasib","paper-codebreak-200-lancet-2023"]},{"group":"history","date":"2023","precision":"year","title":"COMMANDS: luspatercept beats epoetin alfa in first line","note":"Lower-risk myelodysplastic syndromes","from":"mds-lower-risk","refs":["luspatercept","epoetin-alfa"]},{"group":"history","date":"2023","precision":"year","title":"COSMIC-313 triplet fails on OS; CONTACT-03 closes IO rechallenge; belzutifan approved after IO/TKI (LITESPARK-005); ZIRCON validates CAIX PET","note":"Renal cell carcinoma","from":"rcc","refs":["cosmic-313","contact-03","litespark-005","caix-pet"]},{"group":"history","date":"2023","precision":"year","title":"ctDNA and residual cancer burden shown independently prognostic","note":"Triple-negative breast cancer (TNBC). Stecklein's 80-patient registry: ctDNA positive in a third of residual-disease patients, rising with RCB class, with three-year event-free sur...","from":"tnbc","refs":["paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","ctdna-mrd-positive"]},{"group":"history","date":"2023","precision":"year","title":"Dabrafenib plus trametinib in BRAF V600E paediatric high-grade glioma","note":"Paediatric high-grade glioma (excluding diffuse midline glioma). Hargrave and colleagues (JCO) report durable responses in the paediatric cohort.","from":"paediatric-high-grade-glioma","refs":["dabrafenib-trametinib","dabrafenib","trametinib"]},{"group":"history","date":"2023","precision":"year","title":"DESTINY-Lung02 confirms the 5.4 mg/kg dose with less lung inflammation","note":"HER2-mutant non-small-cell lung cancer","from":"her2-mutant-nsclc","refs":["destiny-lung02","trastuzumab-deruxtecan"]},{"group":"history","date":"2023","precision":"year","title":"DIPLOMA: minimally invasive distal pancreatectomy non-inferior for R0 resection in pancreatic cancer","note":"Mucinous cystic neoplasm of the pancreas with associated invasive carcinoma (MCN-associated carcinoma)","from":"mcn-associated-carcinoma","refs":["distal-pancreatectomy","robotic-surgery"]},{"group":"history","date":"2023","precision":"year","title":"DUO-E: durvalumab with chemotherapy, PFS hazard ratio 0.42 in dMMR tumours","note":"Mismatch-repair-deficient endometrial cancer","from":"endometrial-mmr-deficient","refs":["duo-e"]},{"group":"history","date":"2023","precision":"year","title":"E2211 final analysis: CAPTEM beats temozolomide alone","note":"Pancreatic neuroendocrine tumours","from":"pancreatic-net","refs":["capecitabine-temozolomide"]},{"group":"history","date":"2023","precision":"year","title":"EAU-ASCO collaborative guideline","note":"Penile cancer. First joint European and American guideline for penile cancer.","from":"penile","refs":[]},{"group":"history","date":"2023","precision":"year","title":"EAU-ASCO collaborative guideline sets organ preservation and sentinel node biopsy as standards","note":"Localised penile cancer (organ-confined, node-negative)","from":"localised-penile-cancer","refs":["sentinel-node","mohs-surgery"]},{"group":"history","date":"2023","precision":"year","title":"EAU-ASCO guideline codifies node management; HERCULES reports responses to pembrolizumab with chemotherapy","note":"Node-positive and metastatic penile cancer","from":"node-positive-penile-cancer","refs":["lymphadenectomy","pembrolizumab"]},{"group":"history","date":"2023","precision":"year","title":"Eflornithine approved as maintenance on an external-control comparison; GD2 CAR T-cells produce remissions in relapsed disease","note":"High-risk neuroblastoma","from":"neuroblastoma-high-risk","refs":["eflornithine","nmtrc003","gd2-cart01"]},{"group":"history","date":"2023","precision":"year","title":"Elacestrant (EMERALD) and capivasertib (CAPItello-291) approved","note":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","from":"hr-positive-metastatic-post-cdk46","refs":["emerald","elacestrant","capitello-291","capivasertib"]},{"group":"history","date":"2023","precision":"year","title":"Elacestrant (first oral SERD), capivasertib, sacituzumab in HR+","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["elacestrant","emerald","capivasertib","capitello-291"]},{"group":"history","date":"2023","precision":"year","title":"EMBARK: enzalutamide delays metastasis in high-risk biochemical recurrence","note":"Biochemical recurrence of prostate cancer","from":"prostate-bcr","refs":["embark","enzalutamide"]},{"group":"history","date":"2023","precision":"year","title":"Enfortumab vedotin plus pembrolizumab approved for urothelial cancer","note":"Urethral cancer. Applied by extrapolation to urothelial-type urethral carcinoma.","from":"urethral","refs":["enfortumab-vedotin","pembrolizumab"]},{"group":"history","date":"2023","precision":"year","title":"England announces a national lung cancer screening programme","note":"Lung cancer (all types). Announced on 26 June 2023 at a cost of £270 million a year once fully implemented, expected to deliver almost one million scans and find as many as 9,000 c...","from":"lung-cancer","refs":["nhs-targeted-lung-health-check"]},{"group":"history","date":"2023","precision":"year","title":"ESGO / ESTRO / ESP guidance on rare gynaecological cancers includes vaginal cancer","note":"Vaginal cancer","from":"vaginal","refs":["brachytherapy"]},{"group":"history","date":"2023","precision":"year","title":"ESMO guideline codifies the favourable subsets and their treatment","note":"Cancer of unknown primary, favourable subsets","from":"cup-favourable-subsets","refs":["histopathology-ihc"]},{"group":"history","date":"2023","precision":"year","title":"ESMO guideline recommends comprehensive genomic profiling","note":"Cancer of unknown primary (CUP)","from":"cancer-of-unknown-primary","refs":[]},{"group":"history","date":"2023","precision":"year","title":"ESPAC-5: neoadjuvant chemotherapy beats immediate surgery for borderline disease","note":"Borderline resectable pancreatic ductal adenocarcinoma","from":"borderline-resectable-pdac","refs":["gemcitabine","capecitabine","folfirinox"]},{"group":"history","date":"2023","precision":"year","title":"EV-302 doubles survival","note":"Bladder & urothelial cancer","from":"urothelial","refs":["ev-302"]},{"group":"history","date":"2023","precision":"year","title":"EV-302: enfortumab vedotin plus pembrolizumab replaces platinum first line","note":"Muscle-invasive and advanced bladder cancer","from":"muscle-invasive-bladder-cancer","refs":["ev-302"]},{"group":"history","date":"2023","precision":"year","title":"EV-302: EV + pembrolizumab nearly doubles metastatic survival","note":"Bladder & urothelial cancer","from":"urothelial","refs":["ev-302","ev-pembro-continuum"]},{"group":"history","date":"2023","precision":"year","title":"FDA accelerated approval of tucatinib with trastuzumab, the first HER2 approval in colorectal cancer","note":"HER2-amplified colorectal cancer","from":"her2-amplified-colorectal","refs":["tucatinib"]},{"group":"history","date":"2023","precision":"year","title":"FLAURA2 and PAPILLON: chemotherapy added to osimertinib; amivantamab plus chemotherapy for exon 20","note":"EGFR-mutated non-small-cell lung cancer","from":"egfr-mutant-nsclc","refs":["flaura2","nct04538664","amivantamab"]},{"group":"history","date":"2023","precision":"year","title":"FOxTROT: chemotherapy before surgery for locally advanced colon cancer","note":"Colorectal cancer. Six weeks of oxaliplatin and fluoropyrimidine before surgery, then 18 weeks after, left fewer patients with residual or recurrent disease at two years than 24 we...","from":"colorectal","refs":["folfox","capox"]},{"group":"history","date":"2023","precision":"year","title":"GD2 CAR-T phase 1/2 in NEJM","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":[]},{"group":"history","date":"2023","precision":"year","title":"GD2-CART01 in NEJM: durable CAR-T remissions in a solid tumour; eflornithine approved (13 Dec)","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["gd2-cart01","eflornithine","nmtrc003"]},{"group":"history","date":"2023","precision":"year","title":"Glofitamab and epcoritamab approved: off-the-shelf T-cell redirection","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["glofitamab","epcoritamab","epcore-nhl-1"]},{"group":"history","date":"2023","precision":"year","title":"Glofitamab, epcoritamab approved","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["glofitamab"]},{"group":"history","date":"2023","precision":"year","title":"HER2CLIMB-02: tucatinib with trastuzumab emtansine","note":"HER2-positive breast cancer with brain metastases","from":"her2-positive-breast-brain-metastases","refs":["her2climb-02"]},{"group":"history","date":"2023","precision":"year","title":"HERIZON-BTC-01 published; ESMO biliary tract cancer guideline","note":"Gallbladder cancer. Zanidatamab response rate 41.3 percent in HER2-positive disease after chemotherapy.","from":"gallbladder","refs":["herizon-btc-01","paper-harding-lancet-oncol","paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023"]},{"group":"history","date":"2023","precision":"year","title":"Higher-risk combinations fail","note":"Myelodysplastic syndromes / neoplasms (MDS). Magrolimab (ENHANCE) and sabatolimab (STIMULUS-MDS2) add nothing to azacitidine; VERONA (venetoclax) negative in 2024.","from":"mds","refs":["magrolimab","venetoclax","azacitidine"]},{"group":"history","date":"2023","precision":"year","title":"IMbrave050: adjuvant atezolizumab-bevacizumab improves recurrence-free survival at interim analysis","note":"Early hepatocellular carcinoma (BCLC 0 and A)","from":"hcc-early","refs":["imbrave050"]},{"group":"history","date":"2023","precision":"year","title":"IND.227/KEYNOTE-483 positive for pembrolizumab-chemotherapy","note":"Mesothelioma","from":"mesothelioma","refs":["keynote-483"]},{"group":"history","date":"2023","precision":"year","title":"INDIGO: vorasidenib delays progression in grade 2 IDH-mutant glioma","note":"Astrocytoma, IDH-mutant (grades 2 to 4). Mellinghoff and colleagues (NEJM): median progression-free survival 27.7 versus 11.1 months.","from":"idh-mutant-astrocytoma","refs":["vorasidenib","indigo"]},{"group":"history","date":"2023","precision":"year","title":"INDIGO: vorasidenib in grade 2 astrocytoma and oligodendroglioma","note":"Oligodendroglioma, IDH-mutant and 1p/19q-codeleted","from":"oligodendroglioma","refs":["vorasidenib","indigo"]},{"group":"history","date":"2023","precision":"year","title":"INDIGO: vorasidenib in grade 2 IDH-mutant glioma; DCVax-L contested publication","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["indigo","dcvax-l"]},{"group":"history","date":"2023","precision":"year","title":"innovaTV 301 and BEATcc positive","note":"Recurrent or metastatic cervical cancer","from":"recurrent-metastatic-cervical-cancer","refs":["innovatv-301","beatcc"]},{"group":"history","date":"2023","precision":"year","title":"INTERLACE: induction carboplatin-paclitaxel improves five-year survival from 72 to 80 percent","note":"Locally advanced cervical cancer","from":"locally-advanced-cervical-cancer","refs":["interlace"]},{"group":"history","date":"2023","precision":"year","title":"KarMMa-3 and CARTITUDE-4: CAR-T beats standard regimens in randomised trials; talquetamab and elranatamab approved","note":"Relapsed or refractory multiple myeloma","from":"myeloma-relapsed-refractory","refs":["karmma-3","cartitude-4","talquetamab","elranatamab"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-671 and AEGEAN: perioperative pembrolizumab and durvalumab; CALGB 140503: sublobar resection non-inferior","note":"Resectable stage I to III non-small-cell lung cancer","from":"resectable-nsclc","refs":["keynote-671","nct03800134","calgb-140503","heather-wakelee"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-859: pembrolizumab plus chemotherapy extends survival","note":"PD-L1-high gastric cancer","from":"gastric-pdl1-high","refs":["keynote-859","pembrolizumab"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-942: intismeran autogene plus pembrolizumab lowers relapse in phase 2b","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["intismeran-autogene"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-966: pembrolizumab added to chemotherapy","note":"Intrahepatic cholangiocarcinoma","from":"intrahepatic-cholangiocarcinoma","refs":["keynote-966","pembrolizumab"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-966: pembrolizumab confirms chemo-IO","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["keynote-966"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-966: pembrolizumab confirms the class effect","note":"Gallbladder cancer","from":"gallbladder","refs":["keynote-966","pembrolizumab"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-A18 and INTERLACE positive; BEATcc and innovaTV 301 positive","note":"Cervical cancer. Four practice-changing phase 3 results presented at ESMO 2023.","from":"cervical","refs":["keynote-a18","interlace","beatcc","innovatv-301"]},{"group":"history","date":"2023","precision":"year","title":"KEYNOTE-A18: pembrolizumab with chemoradiation improves progression-free and overall survival","note":"Locally advanced cervical cancer","from":"locally-advanced-cervical-cancer","refs":["keynote-a18"]},{"group":"history","date":"2023","precision":"year","title":"KRYSTAL-1 and CodeBreaK 300 show that adding an anti-EGFR antibody makes KRAS G12C inhibitors work in the bowel","note":"KRAS G12C-mutant colorectal cancer","from":"kras-g12c-colorectal","refs":["nct03785249","codebreak-300","adagrasib","sotorasib"]},{"group":"history","date":"2023","precision":"year","title":"LIBRETTO-431: selpercatinib beats chemotherapy plus pembrolizumab first line","note":"RET fusion-positive non-small-cell lung cancer","from":"ret-fusion-nsclc","refs":["libretto-431","selpercatinib","zhou-caicun"]},{"group":"history","date":"2023","precision":"year","title":"LIBRETTO-531: selpercatinib beats cabozantinib/vandetanib in medullary cancer","note":"Thyroid cancer","from":"thyroid","refs":["libretto-531"]},{"group":"history","date":"2023","precision":"year","title":"LIBRETTO-531: selpercatinib beats multikinase inhibitors in RET-mutant MTC","note":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4). Hadoux and colleagues, NEJM.","from":"multiple-endocrine-neoplasia","refs":["selpercatinib","libretto-531"]},{"group":"history","date":"2023","precision":"year","title":"LIBRETTO-531: selpercatinib beats the multikinase drugs first line","note":"Medullary thyroid cancer","from":"medullary-thyroid-cancer","refs":["selpercatinib"]},{"group":"history","date":"2023","precision":"year","title":"Low-dose nivolumab nearly triples one-year survival","note":"Buccal mucosa and gingivobuccal cancer (oral cancer in India)","from":"buccal-mucosa-cancer","refs":["low-dose-nivolumab-tmh"]},{"group":"history","date":"2023","precision":"year","title":"Magrolimab and sabatolimab combinations fail","note":"Higher-risk myelodysplastic syndromes","from":"mds-higher-risk","refs":["magrolimab","sabatolimab"]},{"group":"history","date":"2023","precision":"year","title":"Magrolimab with azacitidine fails in TP53-mutated AML","note":"Secondary and therapy-related acute myeloid leukaemia","from":"aml-secondary","refs":["magrolimab"]},{"group":"history","date":"2023","precision":"year","title":"MAJIC-PV links complete response to fewer events","note":"Polycythaemia vera (PV). Ruxolitinib beat best available therapy after hydroxyurea failure, and complete responders had better event-free survival.","from":"polycythaemia-vera","refs":["majic-pv","ruxolitinib"]},{"group":"history","date":"2023","precision":"year","title":"MARIPOSA beats osimertinib; KEYNOTE-671 perioperative IO; ALINA adjuvant alectinib; repotrectinib approved","note":"Non-small-cell lung cancer","from":"nsclc","refs":["mariposa","keynote-671","alina","repotrectinib"]},{"group":"history","date":"2023","precision":"year","title":"MIRASOL: mirvetuximab soravtansine extends survival, 16.46 versus 12.75 months","note":"Platinum-resistant ovarian cancer","from":"platinum-resistant-ovarian-cancer","refs":["mirasol"]},{"group":"history","date":"2023","precision":"year","title":"Momelotinib approved for anaemic myelofibrosis after MOMENTUM","note":"Primary myelofibrosis","from":"primary-myelofibrosis","refs":["momelotinib"]},{"group":"history","date":"2023","precision":"year","title":"Momelotinib for anaemic myelofibrosis","note":"Myeloproliferative neoplasms (PV, ET, myelofibrosis). MOMENTUM: symptom, spleen and transfusion-independence benefit versus danazol.","from":"myeloproliferative-neoplasms","refs":["momelotinib"]},{"group":"history","date":"2023","precision":"year","title":"MRTX1133 regressions in G12D models; autogene cevumeran phase 1 in Nature","note":"Pancreatic ductal adenocarcinoma","from":"pancreatic","refs":["mrtx1133","autogene-cevumeran"]},{"group":"history","date":"2023","precision":"year","title":"NAPOLI 3: NALIRIFOX beats gemcitabine plus nab-paclitaxel first line","note":"Metastatic pancreatic ductal adenocarcinoma","from":"metastatic-pdac","refs":["napoli-3","nalirifox","zev-wainberg","paper-napoli-3-lancet-2023"]},{"group":"history","date":"2023","precision":"year","title":"NATALEE: adjuvant ribociclib in stage II to III disease","note":"High-risk early HR-positive breast cancer","from":"hr-positive-early-high-risk","refs":["natalee","ribociclib"]},{"group":"history","date":"2023","precision":"year","title":"NEONIPIGA: neoadjuvant nivolumab and ipilimumab give pathological complete response in 59 percent","note":"Microsatellite-unstable (MSI-high) gastric cancer","from":"gastric-msi-high","refs":["nivolumab","ipilimumab"]},{"group":"history","date":"2023","precision":"year","title":"Nirogacestat approved","note":"Desmoid tumour. DeFi phase 3 (NEJM 2023); FDA approval 27 November 2023, the first for desmoid tumours.","from":"desmoid-tumour","refs":["nirogacestat","defi"]},{"group":"history","date":"2023","precision":"year","title":"Nirogacestat: first drug for desmoid tumours","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["nirogacestat"]},{"group":"history","date":"2023","precision":"year","title":"NOTABLE: nimotuzumab plus gemcitabine lengthens survival in KRAS wild-type pancreatic cancer","note":"KRAS wild-type pancreatic ductal adenocarcinoma","from":"kras-wild-type-pdac","refs":["notable-trial","nimotuzumab"]},{"group":"history","date":"2023","precision":"year","title":"PARP + ARPI combinations approved (TALAPRO-2, PROpel, MAGNITUDE); EMBARK for biochemical recurrence","note":"Prostate cancer","from":"prostate","refs":["talapro-2","propel","magnitude","embark"]},{"group":"history","date":"2023","precision":"year","title":"PARP inhibition is confirmed, and the biomarker is shown not to be one thing","note":"Prostate cancer. TRITON3 randomised 405 men and found imaging-based progression-free survival of 11.2 against 6.4 months in the BRCA subgroup, and a hazard ratio of 0.95 in the ATM...","from":"prostate","refs":["paper-fizazi-triton3-rucaparib-nejm-2023","paper-abida-triton2-rucaparib-brca-jco-2020"]},{"group":"history","date":"2023","precision":"year","title":"Percutaneous hepatic perfusion (Hepzato) approved","note":"Uveal melanoma","from":"uveal-melanoma","refs":["percutaneous-hepatic-perfusion","melphalan"]},{"group":"history","date":"2023","precision":"year","title":"PHAROS: encorafenib plus binimetinib approved","note":"BRAF V600E-mutant non-small-cell lung cancer","from":"braf-v600e-nsclc","refs":["pharos","encorafenib","binimetinib","pfizer"]},{"group":"history","date":"2023","precision":"year","title":"PIONEER published; avapritinib approved for indolent systemic mastocytosis","note":"Indolent and smouldering systemic mastocytosis","from":"indolent-systemic-mastocytosis","refs":["avapritinib","nct03731260"]},{"group":"history","date":"2023","precision":"year","title":"Pirtobrutinib and bispecific antibodies report activity in Richter cohorts","note":"Richter transformation of chronic lymphocytic leukaemia","from":"richter-transformation-cll","refs":["pirtobrutinib"]},{"group":"history","date":"2023","precision":"year","title":"Pirtobrutinib approved after BTK and BCL-2 inhibitor failure","note":"Relapsed or refractory chronic lymphocytic leukaemia","from":"cll-relapsed","refs":["pirtobrutinib"]},{"group":"history","date":"2023","precision":"year","title":"Pirtobrutinib approved; ibrutinib US MCL indication withdrawn","note":"Mantle cell lymphoma","from":"mantle-cell-lymphoma","refs":["pirtobrutinib","ibrutinib"]},{"group":"history","date":"2023","precision":"year","title":"PROSPECT: FOLFOX with selective chemoradiation is as good as routine chemoradiation","note":"Rectal cancer","from":"rectal-cancer","refs":["prospect"]},{"group":"history","date":"2023","precision":"year","title":"ProtecT fifteen-year results confirm surveillance","note":"Localised prostate cancer, very low and low risk","from":"prostate-low-risk","refs":["protect"]},{"group":"history","date":"2023","precision":"year","title":"PSMAfore and TALAPRO-2","note":"Metastatic castration-resistant prostate cancer","from":"prostate-mcrpc","refs":["psmafore","talapro-2"]},{"group":"history","date":"2023","precision":"year","title":"QuANTUM-First: quizartinib approved for FLT3-ITD AML up to age 75","note":"FLT3-mutated acute myeloid leukaemia","from":"aml-flt3","refs":["quantum-first","quizartinib"]},{"group":"history","date":"2023","precision":"year","title":"Quizartinib approved in frontline FLT3-ITD AML","note":"Acute myeloid leukaemia. QuANTUM-First OS 31.9 vs 15.1 months, including patients to age 75.","from":"aml","refs":["quizartinib","quantum-first"]},{"group":"history","date":"2023","precision":"year","title":"Randomised trial finds no benefit from systemic chemotherapy in unresectable low-grade mucinous appendiceal adenocarcinoma","note":"Low-grade appendiceal mucinous neoplasm and pseudomyxoma peritonei","from":"low-grade-appendiceal-mucinous-neoplasm","refs":["folfox"]},{"group":"history","date":"2023","precision":"year","title":"Retifanlimab approved; ADMEC-O adjuvant nivolumab positive","note":"Merkel cell carcinoma","from":"merkel-cell-carcinoma","refs":["retifanlimab","nivolumab"]},{"group":"history","date":"2023","precision":"year","title":"RUBY and NRG-GY018: chemo-immunotherapy first line, PFS hazard ratios 0.28 and 0.30 in dMMR tumours","note":"Mismatch-repair-deficient endometrial cancer","from":"endometrial-mmr-deficient","refs":["ruby","nrg-gy018-keynote-868"]},{"group":"history","date":"2023","precision":"year","title":"RUBY, NRG-GY018 and DUO-E: chemo-immunotherapy first line","note":"Advanced or recurrent endometrial cancer","from":"advanced-recurrent-endometrial-cancer","refs":["ruby","nrg-gy018-keynote-868","duo-e"]},{"group":"history","date":"2023","precision":"year","title":"RUBY, NRG-GY018, DUO-E: chemo-immunotherapy first line","note":"Endometrial cancer. Three trials in one year; dostarlimab approved for dMMR (July 2023).","from":"endometrial","refs":["ruby","nrg-gy018-keynote-868","duo-e"]},{"group":"history","date":"2023","precision":"year","title":"RUBY/NRG-GY018: IO first line","note":"Endometrial cancer","from":"endometrial","refs":["dostarlimab"]},{"group":"history","date":"2023","precision":"year","title":"SANO: active surveillance non-inferior after complete response","note":"Oesophageal cancer","from":"esophageal","refs":["sano"]},{"group":"history","date":"2023","precision":"year","title":"SOLO-1 7-year OS benefit; PARP later-line labels narrowed","note":"Ovarian cancer. First-line maintenance benefit confirmed while later-line PARP use retreats after OS imbalances (ARIEL4, SOLO3).","from":"ovarian","refs":["solo-1","rucaparib"]},{"group":"history","date":"2023","precision":"year","title":"SOLO-1 seven-year overall survival: 67.0 versus 46.5 percent","note":"Platinum-sensitive ovarian cancer","from":"platinum-sensitive-ovarian-cancer","refs":["solo-1"]},{"group":"history","date":"2023","precision":"year","title":"SPOTLIGHT and GLOW: Claudin 18.2 validated; KEYNOTE-859","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["spotlight-glow","keynote-859"]},{"group":"history","date":"2023","precision":"year","title":"SPOTLIGHT and GLOW: zolbetuximab plus chemotherapy extends survival","note":"Claudin 18.2-positive gastric cancer","from":"gastric-cldn18-2-positive","refs":["spotlight-glow","zolbetuximab"]},{"group":"history","date":"2023","precision":"year","title":"STATICE: trastuzumab deruxtecan active in HER2-expressing carcinosarcoma","note":"Uterine carcinosarcoma","from":"uterine-carcinosarcoma","refs":["trastuzumab-deruxtecan"]},{"group":"history","date":"2023","precision":"year","title":"SUNLIGHT and FRESCO-2 expand late-line options; tucatinib + trastuzumab first HER2 regimen; NICHE-2 pCR 68%","note":"Colorectal cancer","from":"colorectal","refs":["sunlight","fresco-2","mountaineer","niche-2"]},{"group":"history","date":"2023","precision":"year","title":"SWOG S1826: nivolumab-AVD beats BV-AVD (ASCO plenary)","note":"Hodgkin lymphoma","from":"hodgkin-lymphoma","refs":["swog-s1826"]},{"group":"history","date":"2023","precision":"year","title":"TADPOLE: dabrafenib plus trametinib beats chemotherapy first line","note":"Paediatric low-grade glioma. Higher response rate and longer progression-free survival than carboplatin-vincristine in BRAF V600E pLGG (NEJM); FDA approval in March 2023.","from":"paediatric-low-grade-glioma","refs":["dabrafenib-trametinib","tadpole"]},{"group":"history","date":"2023","precision":"year","title":"Tata Memorial: low-dose nivolumab nearly triples one-year survival","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["low-dose-nivolumab-tmh"]},{"group":"history","date":"2023","precision":"year","title":"Toripalimab approved in the United States for nasopharyngeal carcinoma; hyperfractionated re-irradiation trial published","note":"Recurrent and metastatic nasopharyngeal carcinoma","from":"recurrent-metastatic-nasopharyngeal-carcinoma","refs":["toripalimab","re-irradiation"]},{"group":"history","date":"2023","precision":"year","title":"Toripalimab first US approval for nasopharyngeal carcinoma","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["toripalimab"]},{"group":"history","date":"2023","precision":"year","title":"Toripalimab: first FDA approval for NPC","note":"Nasopharyngeal carcinoma","from":"nasopharyngeal","refs":["toripalimab"]},{"group":"history","date":"2023","precision":"year","title":"TRIDENT-1: repotrectinib approved with activity against G2032R","note":"ROS1-positive non-small-cell lung cancer","from":"ros1-positive-nsclc","refs":["repotrectinib","nct03093116","alexander-drilon"]},{"group":"history","date":"2023","precision":"year","title":"Tumour mutational burden fails where it matters","note":"Non-small-cell lung cancer. In the trials of pembrolizumab with chemotherapy, continuous tissue mutational burden predicts nothing in either histology, and neither do STK11, KEAP1...","from":"nsclc","refs":["paper-keynote-189-407-tmb-jtocrr-2023","paper-keynote-042-tmb-mutations-ann-oncol-2023"]},{"group":"history","date":"2023","precision":"year","title":"Zanubrutinib approved in CLL; ALPINE; pirtobrutinib accelerated approval","note":"Chronic lymphocytic leukaemia. First BTKi to beat ibrutinib head to head; first non-covalent BTKi in CLL (December).","from":"cll","refs":["zanubrutinib","alpine","pirtobrutinib"]},{"group":"law","date":"2023","precision":"year","title":"EU pharmaceutical package reform (2023 proposal)","note":"European Union, regulation.","from":"eu-pharma-package","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"A National Cancer Grid pooled procurement initiative, India","note":"Pramesh CS, Sengar M, Patankar S, et al. Bulletin of the World Health Organization.","from":"paper-pramesh-ncg-pooled-procurement-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two...","note":"Xu B, Ma F, Wang T, et al. International journal of cancer.","from":"paper-nct04454437-int-j-cancer-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"AALL1331: blinatumomab added to chemotherapy in low-risk first relapse of childhood B-ALL","note":"Hogan LE, Brown PA, Ji L, et al. Journal of Clinical Oncology.","from":"paper-aall1331-low-risk-hogan-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplan...","note":"Johnston SRD, Toi M, O'Shaughnessy J, et al. The Lancet Oncology.","from":"paper-monarche-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final res...","note":"Attard G, Murphy L, Clarke NW, et al. The Lancet Oncology.","from":"paper-attard-lancet-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Accurate proteome-wide missense variant effect prediction with AlphaMissense","note":"Cheng J, Novati G, Pan J, et al. Science.","from":"paper-cheng-science","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"ADIUVO: adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma","note":"Terzolo M, Fassnacht M, Perotti P, et al. The Lancet Diabetes and Endocrinology.","from":"paper-adiuvo-adjuvant-mitotane-low-grade-acc-terzolo-lancet-diabetes-endocrinol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT","note":"Francis PA, Fleming GF, Láng I, et al. Journal of Clinical Oncology.","from":"paper-soft-text-j-clin-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial","note":"Tolaney SM, Tarantino P, Graham N, et al. The Lancet Oncology.","from":"paper-apt-trial-lancet-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Alliance A071401: phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations","note":"Brastianos PK, Twohy EL, Gerstner ER, et al. Journal of Clinical Oncology.","from":"paper-a071401-brastianos-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions","note":"Zhou C, Tang KJ, Cho BC, et al. New England Journal of Medicine.","from":"paper-nct04538664-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","note":"Cho BC, Kim DW, Spira AI, et al. Nature Medicine.","from":"paper-chrysalis-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (S...","note":"Dembrower K, Crippa A, Colón E, et al. The Lancet Digital Health.","from":"paper-screentrustcad-dembrower-lancet-digit-health-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes in KEYNOTE-042","note":"Mok TSK, Lopes G, Cho BC, et al. Annals of Oncology.","from":"paper-keynote-042-tmb-mutations-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metast...","note":"Garassino MC, Gadgeel S, Novello S, et al. JTO Clinical and Research Reports.","from":"paper-keynote-189-407-tmb-jtocrr-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Atezolizumab for advanced alveolar soft part sarcoma","note":"Chen AP, Sharon E, O'Sullivan-Coyne G, et al. New England Journal of Medicine.","from":"paper-atezolizumab-alveolar-soft-part-sarcoma-chen-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"AUGMENT-101: revumenib, the first menin inhibitor, in relapsed leukaemias driven by KMT2A rearrangement or NPM1 mutation","note":"Issa GC, Aldoss I, DiPersio J, et al. Nature.","from":"paper-augment-101-revumenib-menin-nature-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"B7-H3 in Brain Malignancies: Immunology and Immunotherapy","note":"Guo X, Chang M, Wang Y, et al. International journal of biological sciences.","from":"paper-b7-h3-glioblastoma-int-j-biol-sci-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Vogel A, Bridgewater J, Edeline J, et al. Annals of Oncology.","from":"paper-esmo-biliary-tract-cancer-guideline-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Blinatumomab added to chemotherapy in infant KMT2A-rearranged acute lymphoblastic leukaemia","note":"van der Sluis IM, de Lorenzo P, Kotecha RS, et al. New England Journal of Medicine.","from":"paper-blinatumomab-infant-all-van-der-sluis-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer","note":"Kunkler IH, Williams LJ, Jack WJL, et al. New England Journal of Medicine.","from":"paper-kunkler-n-engl-j-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma","note":"Rushbrook SM, Kendall TJ, Zen Y, et al. Gut.","from":"paper-bsg-cholangiocarcinoma-guideline-gut-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial","note":"Zhou C, Chen G, Huang Y, et al. Journal of Thoracic Oncology.","from":"paper-camel-j-thorac-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, internatio...","note":"Qin S, Chan SL, Gu S, et al. The Lancet.","from":"paper-qin-lancet","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Krämer A, Bochtler T, Pauli C, et al. Annals of Oncology.","from":"paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CAPItello-291: capivasertib plus fulvestrant in hormone receptor-positive advanced breast cancer","note":"Turner NC, Oliveira M, Howell SJ, et al. New England Journal of Medicine.","from":"paper-capitello-291-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy","note":"San-Miguel J, Dhakal B, Yong K, et al. New England Journal of Medicine.","from":"paper-cartitude-4-cilta-cel-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report","note":"Kim DW, Kim SW, Camidge DR, et al. Journal of Thoracic Oncology.","from":"paper-nct03381274-j-thorac-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CheckMate 76K: adjuvant nivolumab in resected stage IIB or IIC melanoma","note":"Kirkwood JM, Del Vecchio M, Weber J, et al. Nature Medicine.","from":"paper-checkmate-76k-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial","note":"Mackensen A, Haanen JBAG, Koenecke C, et al. Nature Medicine.","from":"paper-mackensen-nat-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CodeBreaK 100: sotorasib in KRAS p.G12C-mutated advanced pancreatic cancer","note":"Strickler JH, Satake H, George TJ, et al. New England Journal of Medicine.","from":"paper-codebreak-100-sotorasib-kras-g12c-pancreatic-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","note":"de Langen AJ, Johnson ML, Mazieres J, et al. The Lancet.","from":"paper-codebreak-200-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"CodeBreaK 300: sotorasib plus panitumumab in chemotherapy-refractory KRAS G12C colorectal cancer","note":"Fakih MG, Salvatore L, Esaki T, et al. New England Journal of Medicine.","from":"paper-codebreak-300-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Colorectal cancer statistics, 2023","note":"Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-colorectal-cancer-statistics-ca-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre...","note":"Aix SP, Ciuleanu TE, Navarro A, et al. The Lancet. Respiratory medicine.","from":"paper-atlantis-lancet-respir-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"COMMANDS: luspatercept versus epoetin alfa as first treatment for anaemia in lower-risk MDS needing transfusions","note":"Platzbecker U, Della Porta MG, Santini V, et al. The Lancet.","from":"paper-commands-luspatercept-mds-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established...","note":"Sigurjonsdottir G, De Marchi T, Ehinger A, et al. Breast Cancer Research.","from":"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Completeness of regional cancer registry data in north-west Russia, 2008 to 2017","note":"Barchuk A, Tursun-Zade R, Nazarova E, et al. BMC cancer.","from":"paper-barchuk-registry-completeness-bmc-cancer-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","note":"Stecklein SR, Kimler BF, Yoder R, et al. npj Breast Cancer.","from":"paper-stecklein-ctdna-rcb-tnbc-residual-disease-npj-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRAS G12C in Patients With NSCLC: Phase 1 Study Results","note":"Li Z, Song Z, Zhao Y, et al. Journal of Thoracic Oncology.","from":"paper-li-j-thorac-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations","note":"Bouffet E, Hansford JR, Garrè ML, et al. New England Journal of Medicine.","from":"paper-bouffet-n-engl-j-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Dabrafenib plus trametinib in relapsed or refractory BRAF V600-mutant paediatric high-grade glioma","note":"Hargrave DR, Terashima K, Hara J, et al. Journal of Clinical Oncology.","from":"paper-hargrave-dabrafenib-trametinib-paediatric-hgg-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"De novo design of protein structure and function with RFdiffusion","note":"Watson JL, Juergens D, Bennett NR, et al. Nature.","from":"paper-watson-nature","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","note":"Ahn MJ, Cho BC, Felip E, et al. New England Journal of Medicine.","from":"paper-dellphi-301-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"DESTINY-Lung02: two doses of trastuzumab deruxtecan in HER2-mutant metastatic non-small-cell lung cancer","note":"Goto K, Goto Y, Kubo T, et al. Journal of Clinical Oncology.","from":"paper-destiny-lung02-goto-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I cl...","note":"Asherie N, Kfir-Erenfeld S, Avni B, et al. Haematologica.","from":"paper-nxc-201-hbi0101-asherie-haematologica-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement","note":"Petersenn S, Fleseriu M, Casanueva FF, et al. Nature reviews. Endocrinology.","from":"paper-petersenn-nat-rev-endocrinol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"DREAMseq (ECOG-ACRIN EA6134): sequencing dabrafenib-trametinib and nivolumab-ipilimumab in BRAF-mutant metastatic melanoma","note":"Atkins MB, Lee SJ, Chmielowski B, et al. Journal of Clinical Oncology.","from":"paper-dreamseq-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study","note":"Ahn MJ, Bondarenko I, Kalinka E, et al. Journal of Thoracic Oncology.","from":"paper-nct03775486-j-thorac-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"EAU-ASCO collaborative guideline on penile cancer, 2023 update","note":"Brouwer OR, Albersen M, Parnham A, et al. European Urology.","from":"paper-eau-asco-penile-cancer-guideline-eur-urol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery: The PREHAB R...","note":"Molenaar CJL, Minnella EM, Coca-Martinez M, et al. JAMA surgery.","from":"paper-molenaar-jama-surg","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Effect of Peritumoral Infiltration of Local Anesthetic Before Surgery on Survival in Early Breast Cancer","note":"Badwe RA, Parmar V, Nair N, et al. Journal of Clinical Oncology.","from":"paper-badwe-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma","note":"Clingan P, Ladwa R, Brungs D, et al. Journal for ImmunoTherapy of Cancer.","from":"paper-ck-301-101-jitc-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from...","note":"Solomon BJ, Bauer TM, Mok TSK, et al. The Lancet. Respiratory medicine.","from":"paper-crown-lancet-respir-med-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the...","note":"Matulonis UA, Lorusso D, Oaknin A, et al. Journal of Clinical Oncology.","from":"paper-mirvetuximab-soravtansine-ovarian-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"EMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer","note":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al. New England Journal of Medicine.","from":"paper-embark-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"EPCORE NHL-1: epcoritamab, a subcutaneous CD20 x CD3 bispecific, in relapsed large B-cell lymphoma including after CAR-T","note":"Thieblemont C, Phillips T, Ghesquieres H, et al. Journal of Clinical Oncology.","from":"paper-epcore-nhl-1-epcoritamab-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Epcoritamab: First Approval","note":"Frampton JE. Drugs.","from":"paper-epcoritamab-dlbcl-drugs-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Equecabtagene Autoleucel: First Approval","note":"Keam SJ. Molecular diagnosis & therapy.","from":"paper-keam-mol-diagn-ther","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","note":"Rodolakis A, Scambia G, Planchamp F, et al. International journal of gynecological cancer.","from":"paper-rodolakis-int-j-gynecol-cancer","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"ESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer","note":"Ghaneh P, Palmer D, Cicconi S, et al. The Lancet Gastroenterology and Hepatology.","from":"paper-espac-5-neoadjuvant-borderline-resectable-pancreatic-lancet-gastro-hep-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial","note":"Routy B, Lenehan JG, Miller WH, et al. Nature Medicine.","from":"paper-mimic-01-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"FGFR2 Inhibition in Cholangiocarcinoma","note":"Vogel A, Segatto O, Stenzinger A, et al. Annual review of medicine.","from":"paper-fgfr2-cholangiocarcinoma-annu-rev-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors","note":"Cole CB, Morelli MP, Fantini M, et al. Journal of experimental & clinical cancer research.","from":"paper-nct03476681-j-exp-clin-cancer-res-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (...","note":"Özgüroğlu M, Kilickap S, Sezer A, et al. The Lancet Oncology.","from":"paper-empower-lung-1-lancet-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1","note":"Nishio M, Ohe Y, Ikeda S, et al. International journal of clinical oncology.","from":"paper-checkmate-227-int-j-clin-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor...","note":"de Castro G, Kudaba I, Wu YL, et al. Journal of Clinical Oncology.","from":"paper-keynote-042-j-clin-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2)","note":"Dasari A, Lonardi S, Garcia-Carbonero R, et al. The Lancet.","from":"paper-dasari-fresco-2-fruquintinib-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"GALAXY: tumour DNA in blood four weeks after bowel cancer surgery predicts relapse tenfold","note":"Kotani D, Oki E, Nakamura Y, et al. Nature Medicine.","from":"paper-galaxy-signatera-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"GLOW: zolbetuximab plus CAPOX in claudin 18.2-positive, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma","note":"Shah MA, Shitara K, Ajani JA, et al. Nature Medicine.","from":"paper-glow-zolbetuximab-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial","note":"Yu Y, Zhou J, Li X, et al. EClinicalMedicine.","from":"paper-nct04270591-eclinicalmedicine-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Gro...","note":"Yu HA, Goto Y, Hayashi H, et al. Journal of Clinical Oncology.","from":"paper-nct04619004-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: ASCO-College of American Pathologists Guideline Update","note":"Wolff AC, Somerfield MR, Dowsett M, et al. Journal of Clinical Oncology.","from":"paper-wolff-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"IL-15 Superagonist NAI in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer","note":"Chamie K, Chang SS, Kramolowsky E, et al. NEJM Evidence.","from":"paper-chamie-nejm-evid","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"IMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma","note":"Qin S, Chen M, Cheng AL, et al. The Lancet.","from":"paper-imbrave050-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"INDIGO: vorasidenib, the first targeted drug for IDH-mutant low-grade glioma","note":"Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. New England Journal of Medicine.","from":"paper-indigo-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Insights into recent findings and clinical application of YAP and TAZ in cancer","note":"Franklin JM, Wu Z, Guan KL. Nature Reviews Cancer.","from":"paper-franklin-nat-rev-cancer","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Integrative Oncology Care of Symptoms of Anxiety and Depression in Adults With Cancer: Society for Integrative Oncology-ASCO Guideline","note":"Carlson LE, Ismaila N, Addington EL, et al. Journal of Clinical Oncology.","from":"paper-carlson-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","note":"Zhou C, Wang Z, Sun M, et al. Nature Cancer.","from":"paper-gemstone-302-nat-cancer-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer","note":"Partridge AH, Niman SM, Ruggeri M, et al. New England Journal of Medicine.","from":"paper-partridge-n-engl-j-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Intraoperative Fluorescence Guidance for Breast Cancer Lumpectomy Surgery","note":"Smith BL, Hunt KK, Carr D, et al. NEJM Evidence.","from":"paper-smith-nejm-evid","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Japanese gastric cancer treatment guidelines 2021 (6th edition)","note":"Japanese Gastric Cancer Association. Gastric cancer.","from":"paper-japanese-gastric-cancer-treatment-guidelines-2021-gastric-cancer-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KarMMa-3: ide-cel CAR-T versus standard regimens in triple-class-exposed relapsed myeloma","note":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. New England Journal of Medicine.","from":"paper-karmma-3-ide-cel-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma","note":"Chu Q, Perrone F, Greillier L, et al. The Lancet.","from":"paper-keynote-483-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KEYNOTE-811: pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma","note":"Janjigian YY, Kawazoe A, Bai Y, et al. The Lancet.","from":"paper-keynote-811-janjigian-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KEYNOTE-859: pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer","note":"Rha SY, Oh DY, Yañez P, et al. The Lancet Oncology.","from":"paper-keynote-859-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KEYNOTE-966: pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","note":"Kelley RK, Ueno M, Yoo C, et al. The Lancet.","from":"paper-keynote-966-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KRYSTAL-1: adagrasib in advanced solid tumours harbouring a KRAS G12C mutation, including pancreatic cancer","note":"Bekaii-Saab TS, Yaeger R, Spira AI, et al. Journal of Clinical Oncology.","from":"paper-krystal-1-adagrasib-kras-g12c-solid-tumours-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"KRYSTAL-1: adagrasib with or without cetuximab in KRAS G12C-mutated colorectal cancer","note":"Yaeger R, Weiss J, Pelster MS, et al. New England Journal of Medicine.","from":"paper-krystal-1-crc-yaeger-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"LIBRETTO-431: first-line selpercatinib versus chemotherapy with or without pembrolizumab in RET fusion-positive lung cancer","note":"Zhou C, Solomon B, Loong HH, et al. New England Journal of Medicine.","from":"paper-libretto-431-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"LIBRETTO-531: selpercatinib versus cabozantinib or vandetanib in advanced RET-mutant medullary thyroid cancer","note":"Hadoux J, Elisei R, Brose MS, et al. New England Journal of Medicine.","from":"paper-libretto-531-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer","note":"Altorki N, Wang X, Kozono D, et al. New England Journal of Medicine.","from":"paper-calgb-140503-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Low-dose immunotherapy in head and neck cancer: a randomised study (Tata Memorial)","note":"Patil VM, Noronha V, Menon N, et al. Journal of Clinical Oncology.","from":"paper-patil-low-dose-nivolumab-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Lung adenocarcinoma promotion by air pollutants","note":"Hill W, Lim EL, Weeden CE, et al. Nature.","from":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments","note":"Authors not listed. Journal not given.","from":"paper-lutetium-177-vipivotide-tetrax-prostate-journal-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial","note":"Kishan AU, Ma TM, Lamb JM, et al. JAMA Oncology.","from":"paper-kishan-jama-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"MagnetisMM-3: elranatamab, a second BCMA bispecific, with a switch to fortnightly dosing after response","note":"Lesokhin AM, Tomasson MH, Arnulf B, et al. Nature Medicine.","from":"paper-magnetismm-3-elranatamab-natmed-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload","note":"Lång K, Josefsson V, Larsson AM, et al. Lancet Oncology.","from":"paper-masai-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: phase 1/2 trial interim results","note":"Hassan R, Butler M, O'Cearbhaill RE, et al. Nature Medicine.","from":"paper-nct03907852-nat-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Metastasis","note":"Gerstberger S, Jiang Q, Ganesh K. Cell.","from":"paper-gerstberger-cell","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Cervantes A, Adam R, Roselló S, et al. Annals of Oncology.","from":"paper-esmo-metastatic-colorectal-cancer-guideline-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"MIRASOL: mirvetuximab soravtansine versus chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer","note":"Moore KN, Angelergues A, Konecny GE, et al. New England Journal of Medicine.","from":"paper-mirasol-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"MOMENTUM: momelotinib versus danazol for myelofibrosis patients with anaemia after a prior JAK inhibitor","note":"Verstovsek S, Gerds AT, Vannucchi AM, et al. The Lancet.","from":"paper-momentum-momelotinib-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer","note":"Engstrom LD, Aranda R, Waters L, et al. Cancer Discovery.","from":"paper-engstrom-cancer-discov","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"NAPOLI-3: NALIRIFOX versus gemcitabine plus nab-paclitaxel as first treatment for metastatic pancreatic cancer","note":"Wainberg ZA, Melisi D, Macarulla T, et al. The Lancet.","from":"paper-napoli-3-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma","note":"Patel SP, Othus M, Chen Y, et al. New England Journal of Medicine.","from":"paper-swog-s1801-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer","note":"Qin S, Li J, Bai Y, et al. Journal of Clinical Oncology.","from":"paper-qin-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer","note":"Chi KN, Rathkopf D, Smith MR, et al. Journal of Clinical Oncology.","from":"paper-magnitude-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors","note":"Gounder M, Ratan R, Alcindor T, et al. New England Journal of Medicine.","from":"paper-gounder-n-engl-j-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"NRG-GY018: pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer","note":"Eskander RN, Sill MW, Beffa L, et al. New England Journal of Medicine.","from":"paper-nrg-gy018-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)","note":"Ring A, Kilburn LS, Pearson A, et al. Clinical Cancer Research.","from":"paper-ring-clin-cancer-res","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival resul...","note":"Saad F, Clarke NW, Oya M, et al. The Lancet Oncology.","from":"paper-propel-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer","note":"Whelan TJ, Smith S, Parpia S, et al. New England Journal of Medicine.","from":"paper-lumina-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","note":"Planchard D, Jänne PA, Cheng Y, et al. New England Journal of Medicine.","from":"paper-planchard-flaura2-osimertinib-chemotherapy-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"OUTBACK: adjuvant carboplatin-paclitaxel after chemoradiotherapy for locally advanced cervical cancer","note":"Mileshkin LR, Moore KN, Barnes EH, et al. The Lancet Oncology.","from":"paper-outback-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Outcome of ivermectin in cancer treatment: an experience in Loja, Ecuador","note":"Jiménez-Gaona Y, Vivanco-Galván O, Morales-Larreategui G, Cabrera-Bejarano A, Lakshminarayanan V. Nursing Reports.","from":"paper-jimenez-gaona-ivermectin-loja-ecuador-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma","note":"Long GV, Stephen Hodi F, Lipson EJ, et al. NEJM Evidence.","from":"paper-relativity-047-nejm-evid-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, ope...","note":"Felip E, Altorki N, Zhou C, et al. Annals of Oncology.","from":"paper-nct02486718-ann-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF V600 mutation-positive advanced melanoma (IMspire150): sec...","note":"Ascierto PA, Stroyakovskiy D, Gogas H, et al. The Lancet Oncology.","from":"paper-imspire150-lancet-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS...","note":"Rugo HS, Bardia A, Marmé F, et al. The Lancet.","from":"paper-tropics-02-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Conroy T, Pfeiffer P, Vilgrain V, et al. Annals of Oncology.","from":"paper-esmo-pancreatic-cancer-guideline-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Ca...","note":"Watanabe J, Muro K, Shitara K, et al. JAMA.","from":"paper-paradigm-jama-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms","note":"Schrag D, Beer TM, McDonnell CH, et al. The Lancet.","from":"paper-pathfinder-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket tria...","note":"Blay JY, Chevret S, Le Cesne A, et al. The Lancet Oncology.","from":"paper-blay-lancet-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study","note":"Novello S, Kowalski DM, Luft A, et al. Journal of Clinical Oncology.","from":"paper-keynote-407-j-clin-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Perioperative durvalumab for resectable non-small-cell lung cancer","note":"Heymach JV, Harpole D, Mitsudomi T, et al. New England Journal of Medicine.","from":"paper-heymach-aegean-perioperative-durvalumab-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Perioperative nivolumab and chemotherapy in stage III non-small-cell lung cancer","note":"Provencio M, Nadal E, Gonzalez-Larriba JL, et al. New England Journal of Medicine.","from":"paper-provencio-nadim-ii-perioperative-nivolumab-stage-iii-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer","note":"Wakelee H, Liberman M, Kato T, et al. New England Journal of Medicine.","from":"paper-keynote-671-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"PHAROS: encorafenib plus binimetinib in BRAF V600E-mutant metastatic non-small-cell lung cancer","note":"Riely GJ, Smit EF, Ahn MJ, et al. Journal of Clinical Oncology.","from":"paper-pharos-encorafenib-binimetinib-riely-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma","note":"de Vries EGE, Rüschoff J, Lolkema M, et al. Cancer medicine.","from":"paper-luca-gianni-cancer-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Phase II, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor-T-Cell Therapy, in Chinese Patients With Re...","note":"Mi JQ, Zhao W, Jing H, et al. Journal of Clinical Oncology.","from":"paper-ciltacabtagene-autoleucel-multiple-myeloma-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"PIONEER: avapritinib versus placebo in indolent systemic mastocytosis","note":"Gotlib J, Castells M, Elberink HO, et al. NEJM Evidence.","from":"paper-pioneer-avapritinib-indolent-systemic-mastocytosis-nejm-evid-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial (FOxTROT)","note":"Morton D, Seymour M, Magill L, et al. Journal of Clinical Oncology.","from":"paper-foxtrot-preoperative-chemotherapy-colon-jco-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group","note":"Karschnia P, Young JS, Dono A, et al. Neuro-Oncology.","from":"paper-karschnia-neuro-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"PROSPECT: neoadjuvant FOLFOX with selective use of chemoradiotherapy for locally advanced rectal cancer","note":"Schrag D, Shi Q, Weiser MR, et al. New England Journal of Medicine.","from":"paper-prospect-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"ProtecT: fifteen-year outcomes after monitoring, surgery or radiotherapy for prostate cancer","note":"Hamdy FC, Donovan JL, Lane JA, et al. New England Journal of Medicine.","from":"paper-protect-15-year-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Proton FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases: The FAST-01 Nonrandomized Trial","note":"Mascia AE, Daugherty EC, Zhang Y, et al. JAMA Oncology.","from":"paper-mascia-jama-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"QuANTUM-First: quizartinib added to intensive chemotherapy and continued as maintenance in newly diagnosed FLT3-ITD AML","note":"Erba HP, Montesinos P, Kim HJ, et al. The Lancet.","from":"paper-quantum-first-quizartinib-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III tri...","note":"Omuro A, Brandes AA, Carpentier AF, et al. Neuro-Oncology.","from":"paper-omuro-neuro-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Randomized Double-Blind Placebo-Controlled Study of Olanzapine for Chemotherapy-Related Anorexia in Patients With Locally Advanced or Metastatic Gastric, Hepato...","note":"Sandhya L, Devi Sreenivasan N, Goenka L, et al. Journal of Clinical Oncology.","from":"paper-sandhya-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma","note":"Chesney JA, Ribas A, Long GV, et al. Journal of Clinical Oncology.","from":"paper-chesney-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","note":"Wen PY, van den Bent M, Youssef G, et al. Journal of Clinical Oncology.","from":"paper-andrew-lassman-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Red Blood Cell Transfusion: 2023 AABB International Guidelines","note":"Carson JL, Stanworth SJ, Guyatt G, et al. JAMA.","from":"paper-carson-jama","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a p...","note":"Sonabend AM, Gould A, Amidei C, et al. The Lancet Oncology.","from":"paper-sonabend-lancet-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients wit...","note":"Turner NC, Swift C, Jenkins B, et al. Annals of Oncology.","from":"paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"RNA splicing dysregulation and the hallmarks of cancer","note":"Bradley RK, Anczuków O. Nature Reviews Cancer.","from":"paper-bradley-nat-rev-cancer","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Rojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer","note":"Rojas LA, Sethna Z, Soares KC, et al. Nature.","from":"paper-rojas-mrna-neoantigen-vaccine-pancreatic-nature-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"RUBY: dostarlimab with chemotherapy for advanced or recurrent endometrial cancer","note":"Mirza MR, Chase DM, Slomovitz BM, et al. New England Journal of Medicine.","from":"paper-ruby-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial","note":"Harrison CN, Nangalia J, Boucher R, et al. Journal of Clinical Oncology.","from":"paper-harrison-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Seed-displacements in the immediate post-implant phase in permanent prostate brachytherapy","note":"Karius A, Schweizer C, Strnad V, et al. Radiotherapy and Oncology.","from":"paper-karius-radiother-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","note":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. New England Journal of Medicine.","from":"paper-lincoff-n-engl-j-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Shalhout 2023: what the approved oncolytic viruses actually do in practice","note":"Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Nature Reviews Clinical Oncology.","from":"paper-shalhout-oncolytic-progress-challenges-natrevclinonc-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Siegel 2023: Cancer statistics, 2023","note":"Siegel RL, Miller KD, Wagle NS, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2023-cacancer-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical Trial","note":"Xu J, Jiang H, Pan Y, et al. JAMA.","from":"paper-xu-jama","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","note":"Shitara K, Lordick F, Bang YJ, et al. The Lancet.","from":"paper-spotlight-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography","note":"Mikhael PG, Wohlwend J, Yala A, et al. Journal of Clinical Oncology.","from":"paper-mikhael-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 tria...","note":"Agarwal N, Azad AA, Carles J, et al. The Lancet.","from":"paper-talapro-2-lancet-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors","note":"Lanzi C, Arrighetti N, Pasquali S, et al. Biochemical pharmacology.","from":"paper-ezh2-sarcoma-biochem-pharmacol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer: Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial","note":"Mazieres J, Paik PK, Garassino MC, et al. JAMA Oncology.","from":"paper-nct02864992-jama-oncol-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"The 2023 Bethesda System for Reporting Thyroid Cytopathology","note":"Ali SZ, Baloch ZW, Cochand-Priollet B, et al. Thyroid.","from":"paper-ali-thyroid","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","note":"de Visser KE, Joyce JA. Cancer Cell.","from":"paper-de-visser-cancer-cell","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"The NCI-MATCH trial: lessons for precision oncology","note":"O'Dwyer PJ, Gray RJ, Flaherty KT, et al. Nature Medicine.","from":"paper-o-dwyer-nat-med","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma","note":"Hassel JC, Piperno-Neumann S, Rutkowski P, et al. New England Journal of Medicine.","from":"paper-imcgp100-202-n-engl-j-med-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial","note":"Mai HQ, Chen QY, Chen D, et al. JAMA.","from":"paper-mai-jama","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"TRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse","note":"Frankell AM, Dietzen M, Al Bakir M, et al. (TRACERx Consortium). Nature.","from":"paper-tracerx-evolution-nature-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Transfer learning enables predictions in network biology","note":"Theodoris CV, Xiao L, Chopra A, et al. Nature.","from":"paper-theodoris-nature","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised...","note":"Hurvitz SA, Hegg R, Chung WP, et al. The Lancet.","from":"paper-destiny-breast03-lancet-2023-update","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)","note":"Prager GW, Taieb J, Fakih M, et al. New England Journal of Medicine.","from":"paper-prager-sunlight-trifluridine-tipiracil-bevacizumab-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"TRITON3: rucaparib or physician's choice in metastatic castration-resistant prostate cancer","note":"Fizazi K, Piulats JM, Reaume MN, et al. New England Journal of Medicine.","from":"paper-fizazi-triton3-rucaparib-nejm-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Bask...","note":"Nakamura Y, Mizuno N, Sunakawa Y, et al. Journal of Clinical Oncology.","from":"paper-nct04579380-j-clin-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER)","note":"Strickler JH, Cercek A, Siena S, et al. The Lancet Oncology.","from":"paper-strickler-mountaineer-tucatinib-trastuzumab-lancet-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with...","note":"Curigliano G, Burstein HJ, Gnant M, et al. Annals of Oncology.","from":"paper-st-gallen-2023-consensus-ann-oncol-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update","note":"Key NS, Khorana AA, Kuderer NM, et al. Journal of Clinical Oncology.","from":"paper-key-j-clin-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","note":"Harding JJ, Fan J, Oh DY, et al. The Lancet Oncology.","from":"paper-harding-lancet-oncol","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia","note":"Brown JR, Eichhorst B, Hillmen P, et al. New England Journal of Medicine.","from":"paper-zanubrutinib-cll-n-engl-j-med-2023","refs":[]},{"group":"paper","date":"2023","precision":"year","title":"γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a ph...","note":"Cowan AJ, Pont MJ, Sather BD, et al. The Lancet Oncology.","from":"paper-cowan-lancet-oncol","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"A Systematic Review and Multilevel Regression Analysis Reveals the Comorbidity Prevalence in Cancer","note":"Cancer Res","from":"haiko-bloemendal","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C","note":"New England Journal of Medicine","from":"tanios-bekaii-saab","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK)","note":"Lancet Oncology","from":"linda-mileshkin","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Adjuvant osimertinib for resected EGFR-mutated NSCLC: overall survival (ADAURA)","note":"NEJM","from":"roy-herbst","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Africa Guidelines for Hepatocellular Carcinoma Buildup Process","note":"JCO Glob Oncol","from":"adda-bounedjar","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation","note":"Immunity","from":"pavan-reddy","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study","note":"Lancet Digital Health","from":"per-hall","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","note":"NEJM Evidence","from":"daniel-spratt","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clini...","note":"Lancet Oncology","from":"kristina-lang","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Assessment of Lung Cancer YouTube Videos for Patient Education","note":"Journal of Cancer Education","from":"paris-ann-ingledew","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy","note":"JAMA Oncology","from":"richard-schulick","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibito...","note":"Lancet","from":"sumanta-pal","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase...","note":"Nature Communications","from":"karen-kelly","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Base-edited CAR7 T cells for relapsed T-cell acute lymphoblastic leukemia","note":"NEJM","from":"waseem-qasim","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Baseline gut microbiota composition is associated with oral mucositis and tumour recurrence in patients with head and neck cancer: a pilot study","note":"Supportive Care in Cancer","from":"hien-le","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Easter...","note":"Journal of Clinical Oncology","from":"peter-odwyer","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors","note":"Biomedicines","from":"janja-ocvirk","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study","note":"Lancet","from":"deb-schrag","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Building resilient cervical cancer prevention through gender-neutral HPV vaccination","note":"eLife","from":"basu-partha","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310)","note":"Lancet","from":"qin-shukui","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Cancer disparities in Southeast Asia: intersectionality and a call to action","note":"The Lancet Regional Health - Western Pacific","from":"gerardo-legaspi","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Cancer treatments touch a wide range of values that count for patients and other stakeholders: What are the implications for decision-making?","note":"Cancer Med","from":"haiko-bloemendal","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Capivasertib in hormone receptor-positive advanced breast cancer (CAPItello-291)","note":"NEJM","from":"nicholas-turner","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Carotid Plaque-RADS","note":"JACC. Cardiovascular imaging","from":"daniel-staub","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Cervical Cancer in Bangladesh","note":"South Asian Journal of Cancer","from":"mostafa-aziz-sumon","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Characteristics of chief investigators and principal investigators in Australian and New Zealand radiation oncology clinical trials","note":"Journal of Medical Imaging and Radiation Oncology","from":"purnima-sundaresan","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Common Sense Oncology: outcomes that matter","note":"Lancet Oncology","from":"christopher-booth","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","note":"Nature Medicine","from":"dancey-janet","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Current perspectives for external control arms in oncology clinical trials: Analysis of EMA approvals 2016–2021","note":"Journal of Cancer Policy","from":"roman-rouzier","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Delays in seeking, reaching and access to quality cancer care in sub-Saharan Africa: a systematic review","note":"BMJ Open","from":"susan-msadabwe","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients","note":"Journal of Experimental & Clinical Cancer Research","from":"christian-singer","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Digital solution in the follow-up of early breast cancer a randomized study","note":"Acta Oncologica","from":"johanna-mattson","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Dostarlimab for primary advanced or recurrent endometrial cancer (RUBY)","note":"NEJM","from":"mansoor-raza-mirza","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial","note":"JAMA","from":"jonathan-benger","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Early-Stage Breast Cancer Detection in Breast Milk","note":"Cancer Discovery","from":"joaquin-arribas","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (...","note":"Lancet","from":"uwe-platzbecker","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Efficient detection and monitoring of pediatric brain malignancies with liquid biopsy based on patient-specific somatic mutation screening","note":"Neuro-Oncology","from":"brandon-wainwright","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II...","note":"JCO","from":"catherine-thieblemont","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update","note":"European Urology","from":"shahrokh-f-shariat","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023","note":"International Journal of Gynecological Cancer","from":"ate-van-der-zee","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Evaluating the childcare needs of cancer patients undergoing radiation therapy","note":"Supportive Care in Cancer","from":"paris-ann-ingledew","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Evaluation of Survival Following Surgical Resection for Small Nonfunctional Pancreatic Neuroendocrine Tumors","note":"JAMA Network Open","from":"richard-schulick","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial","note":"Nature Cancer","from":"sascha-dietrich","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation","note":"Nature Medicine","from":"pavan-reddy","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","note":"New England Journal of Medicine","from":"jenny-donovan","refs":["freddie-hamdy"]},{"group":"person-paper","date":"2023","precision":"year","title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including...","note":"Haematologica","from":"steven-le-gouill","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"FinnGen provides genetic insights from a well-phenotyped isolated population","note":"Nature","from":"arto-mannermaa","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan i...","note":"Journal of Clinical Oncology","from":"yamamoto-noboru","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"First-line venetoclax combinations in chronic lymphocytic leukemia (CLL13/GAIA)","note":"NEJM","from":"barbara-eichhorst","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Fruquintinib versus placebo in refractory metastatic colorectal cancer (FRESCO-2)","note":"Lancet","from":"kim-tae-won","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma (FOENIX-CCA2)","note":"NEJM","from":"lipika-goyal","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Genome-wide CRISPR screening identifies a role for ARRDC3 in TRP53-mediated responses","note":"Cell Death & Differentiation","from":"marco-herold","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis","note":"Frontiers in Oncology","from":"roman-rouzier","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Genotype-phenotype mapping of a patient-derived lung cancer organoid biobank identifies NKX2-1-defined Wnt dependency in lung adenocarcinoma","note":"Cell Reports","from":"koichi-fukunaga","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Goals of Care Among Parents of Children Receiving Palliative Care","note":"JAMA Pediatrics","from":"tammy-kang","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Head and neck cancer burden in India: an analysis from published data of 37 population-based cancer registries","note":"ecancermedicalscience","from":"chaturvedi-pankaj","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Head-to-head comparison of [18F]-FDG and [68 Ga]-DOTA-FAPI-04 PET/CT for radiological evaluation of platinum-sensitive recurrent ovarian cancer","note":"European Journal of Nuclear Medicine and Molecular Imaging","from":"song-shaoli","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC after EGFR TKI therapy and platinum-based chemotherapy","note":"Journal of Clinical Oncology","from":"helena-yu","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable...","note":"Lancet Gastroenterology and Hepatology","from":"paula-ghaneh","refs":["daniel-palmer","chris-halloran"]},{"group":"person-paper","date":"2023","precision":"year","title":"Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)","note":"International Journal of Oncology","from":"lin-tongyu","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"ISSCR standards for the use of human stem cells in basic research","note":"Stem Cell Reports","from":"maneesha-inamdar","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Lenvatinib plus transarterial chemoembolization for unresectable hepatocellular carcinoma (LAUNCH)","note":"JCO","from":"masatoshi-kudo","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Long-Term Outcomes of TROG 13.01 SAFRON II Randomized Trial of Single- Versus Multifraction Stereotactic Ablative Body Radiotherapy for Pulmonary Oligometastase...","note":"Journal of Clinical Oncology","from":"hien-le","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Lorlatinib for ALK-driven relapsed or refractory neuroblastoma (NANT 2015-02)","note":"Nature Medicine","from":"yael-mosse","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Low-dose immunotherapy in head and neck cancer: a randomized study","note":"Journal of Clinical Oncology","from":"patil-vijay","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study","note":"The Lancet Diabetes and Endocrinology","from":"nikhil-tandon","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer","note":"New England Journal of Medicine","from":"ursula-matulonis","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer (MIRASOL)","note":"NEJM","from":"kathleen-moore","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer (GALAXY)","note":"Nature Medicine","from":"yoshino-takayuki","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"MOUNTAINEER: tucatinib plus trastuzumab for HER2-positive, RAS wild-type metastatic colorectal cancer","note":"The Lancet Oncology","from":"john-strickler","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA c...","note":"Br J Surg","from":"pamela-buchwald","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Mutant p53 sustains serine-glycine synthesis and essential amino acids intake promoting breast cancer growth","note":"Nature Communications","from":"giovanni-blandino","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3)","note":"Lancet","from":"zev-wainberg","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-labe...","note":"The Lancet","from":"igor-kiss","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology","note":"NPJ Precision Oncology","from":"hanno-glimm","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant Chemotherapy Versus Upfront Surgery for Resectable Pancreatic Adenocarcinoma","note":"Annals of Surgery","from":"richard-schulick","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant Chemotherapy, Excision, and Observation for Early Rectal Cancer: The Phase II NEO Trial (CCTG CO.28) Primary End Point Results","note":"Journal of Clinical Oncology","from":"hagen-kennecke","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial","note":"Cancer Discovery","from":"julio-oliveira","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial","note":"J Cancer Res Clin Oncol","from":"adda-bounedjar","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant immunotherapy for melanoma: the path forward","note":"Nature Reviews Clinical Oncology","from":"sapna-patel","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability-High Gastric or Esophagogastric J...","note":"J Clin Oncol","from":"christophe-tournigand","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801)","note":"NEJM","from":"sapna-patel","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer","note":"Nature","from":"jean-pierre-delord","refs":["patrick-mehlen"]},{"group":"person-paper","date":"2023","precision":"year","title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","note":"Annals of Oncology","from":"antonio-gonzalez-martin","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Niraparib and abiraterone acetate for metastatic castration-resistant prostate cancer (MAGNITUDE)","note":"JCO","from":"kim-chi","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Result...","note":"Journal of Clinical Oncology","from":"andrzej-kawecki","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial","note":"Annals of Oncology","from":"isabelle-ray-coquard","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer (LUMINA)","note":"NEJM","from":"timothy-whelan","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Organoid Cultures for the Study of Mammary Biology and Breast Cancer: The Promise and Challenges","note":"Cold Spring Harbor Perspectives in Medicine","from":"senthil-muthuswamy","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Overall survival after hyperthermic intraperitoneal chemotherapy for ovarian cancer: 10-year follow-up of OVHIPEC-1","note":"Lancet Oncology","from":"willemien-van-driel","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 300...","note":"Journal of Clinical Oncology","from":"giovanni-scambia","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy in left-sided RAS wild-type metastatic colorectal cancer (PARADIGM)","note":"JAMA","from":"yoshino-takayuki","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Patritumab Deruxtecan (HER3-DXd), a Human Epidermal Growth Factor Receptor 3–Directed Antibody-Drug Conjugate, in Patients With Previously Treated Human Epiderm...","note":"Journal of Clinical Oncology","from":"yonemori-kan","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT...","note":"Annals of Oncology","from":"eva-ciruelos","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer (NRG-GY018)","note":"NEJM","from":"ramez-eskander","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859)","note":"Lancet Oncology","from":"rha-sun-young","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blin...","note":"Lancet Oncol","from":"maeve-lowery","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Performance of standardised colposcopy to detect cervical precancer and cancer for triage of women testing positive for human papillomavirus: results from the E...","note":"The Lancet Global Health","from":"carolina-wiesner","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","note":"Nature","from":"vinod-balachandran","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Phase 2 trial of SurVaxM with temozolomide in newly diagnosed glioblastoma","note":"Journal of Clinical Oncology","from":"robert-fenstermaker","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","note":"Lancet Haematology","from":"elias-jabbour","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy","note":"eLife","from":"richard-van-etten","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Preoperative treatment of locally advanced rectal cancer (PROSPECT)","note":"NEJM","from":"deb-schrag","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Prevalence of smoldering multiple myeloma based on nationwide screening","note":"Nature Medicine","from":"sigurdur-kristinsson","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma","note":"Journal of Clinical Oncology","from":"thomas-george","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA)...","note":"BMJ","from":"ma-fei","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil","note":"Cancer Treatment and Research Communications","from":"katz-artur","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Regulatory Issues: PMDA – Review of Sakigake Designation Products: Oncolytic Virus Therapy with Delytact Injection (Teserpaturev) for Malignant Glioma","note":"The Oncologist","from":"yasuhiro-fujiwara","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Research priorities for children’s cancer: a James Lind Alliance Priority Setting Partnership in the UK","note":"BMJ Open","from":"ashley-ball-gamble","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study","note":"Gynecologic Oncology","from":"ane-gerda-eriksson","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Selpercatinib in RET-mutant medullary thyroid cancer (LIBRETTO-531)","note":"NEJM","from":"lori-wirth","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation","note":"New England Journal of Medicine","from":"armando-santoro","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Smart Start: rituximab, lenalidomide, and ibrutinib in patients with newly diagnosed large B-cell lymphoma","note":"JCO","from":"jason-westin","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multid...","note":"Critical Reviews in Oncology/Hematology","from":"alessandro-delle-donne","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: the FUTURE phase II umbrella clinical trial","note":"Cell Research","from":"shao-zhi-ming","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"SUNLIGHT: trifluridine-tipiracil plus bevacizumab in refractory metastatic colorectal cancer","note":"New England Journal of Medicine","from":"gerald-prager","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Surgical outcomes from the phase 3 CheckMate 816 trial: nivolumab plus platinum-doublet chemotherapy vs chemotherapy alone as neoadjuvant treatment for resectab...","note":"JAMA Oncology","from":"jonathan-spicer","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma (ZUMA-7)","note":"NEJM","from":"jason-westin","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies","note":"Cancer Medicine","from":"ruben-mesa","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"The association of miR-204 and mir-483 5p expression with clinicopathological features of Wilms tumor: Could this provide foresight?","note":"Jpn J Clin Oncol","from":"refik-emre-cecen","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"The evolution of non-small cell lung cancer metastases in TRACERx","note":"Nature","from":"charles-swanton","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","note":"Nature","from":"eytan-stein","refs":["ghayas-issa"]},{"group":"person-paper","date":"2023","precision":"year","title":"Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies","note":"Cancer Cell","from":"tim-somervaille","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Towards elimination of cervical cancer – human papillomavirus (HPV) vaccination and cervical cancer screening in Asian National Cancer Centers Alliance (ANCCA)...","note":"The Lancet Regional Health - Western Pacific","from":"basu-partha","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Trastuzumab Deruxtecan in Patients With HER2 -Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial","note":"Journal of Clinical Oncology","from":"goto-koichi","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Treatment and follow‐up of children with chronic myeloid leukaemia in chronic phase (CML‐CP) in the tyrosine kinase inhibitor (TKI) era—Two decades of experienc...","note":"British Journal of Haematology","from":"narula-gaurav","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Vorasidenib in IDH1- or IDH2-mutant low-grade glioma (INDIGO)","note":"NEJM","from":"ingo-mellinghoff","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","note":"Nature","from":"dan-theodorescu","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia (ALPINE)","note":"NEJM","from":"jennifer-brown","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or GEJ adenocarcinoma (GLOW)","note":"Nature Medicine","from":"ryu-min-hee","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive gastric or GEJ adenocarcinoma (SPOTLIGHT)","note":"Lancet","from":"shitara-kohei","refs":[]},{"group":"person-paper","date":"2023","precision":"year","title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma (SPOTLIGHT)","note":"Lancet","from":"kang-yoon-koo","refs":[]},{"group":"regulatory","date":"2023","precision":"year","title":"Talicabtagene autoleucel: approval (IN)","note":"CDSCO/DCGI market authorisation; the developer's page gives the year only","from":"talicabtagene-autoleucel","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"AlphaMissense","note":"First use in humans or first approval, as the technology record states it.","from":"alphamissense","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Biology-guided radiotherapy (RefleXion X1, SCINTIX)","note":"First use in humans or first approval, as the technology record states it.","from":"biology-guided-radiotherapy","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Bispecific ADC","note":"First use in humans or first approval, as the technology record states it.","from":"bispecific-adc","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Gamma-secretase inhibitors","note":"First use in humans or first approval, as the technology record states it.","from":"gamma-secretase-inhibitors","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"GEARS and perturbation prediction benchmarks","note":"First use in humans or first approval, as the technology record states it.","from":"gears","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Geneformer","note":"First use in humans or first approval, as the technology record states it.","from":"geneformer","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"GenePT","note":"First use in humans or first approval, as the technology record states it.","from":"genept","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"NVIDIA BioNeMo","note":"First use in humans or first approval, as the technology record states it.","from":"bionemo","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Oral SERDs","note":"First use in humans or first approval, as the technology record states it.","from":"oral-serds","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Phikon / Phikon-v2 (Owkin)","note":"First use in humans or first approval, as the technology record states it.","from":"phikon","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"RadFM (generalist radiology foundation model)","note":"First use in humans or first approval, as the technology record states it.","from":"radfm","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)","note":"First use in humans or first approval, as the technology record states it.","from":"rfdiffusion","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Sybil (MIT/MGH lung cancer risk from CT)","note":"First use in humans or first approval, as the technology record states it.","from":"sybil","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Tempus multimodal models","note":"First use in humans or first approval, as the technology record states it.","from":"tempus-multimodal","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"TROP2 PET","note":"First use in humans or first approval, as the technology record states it.","from":"trop2-pet","refs":[]},{"group":"technology","date":"2023","precision":"year","title":"Universal Cell Embedding (UCE)","note":"First use in humans or first approval, as the technology record states it.","from":"universal-cell-embedding","refs":[]},{"group":"trial","date":"2023","precision":"year","title":"A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) reported","note":"Objective response 40 percent at the 10 mg dose and 32 percent at 100 mg in previously treated small-cell lung cancer; median progression-free survival 4.9 and 3.9 months.","from":"nct05060016","refs":["sclc","tarlatamab"]},{"group":"trial","date":"2023","precision":"year","title":"A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. reported","from":"nct02734004","refs":["ovarian","sclc","gastric","olaparib"]},{"group":"trial","date":"2023","precision":"year","title":"A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer reported","from":"nct03790111","refs":["biliary-tract-cancer","cholangiocarcinoma","telotristat-ethyl"]},{"group":"trial","date":"2023","precision":"year","title":"A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Est...","from":"nct04576455","refs":["breast-hr-positive","giredestrant","fulvestrant"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL reported","from":"nct02970318","refs":["cll","cll-relapsed","acalabrutinib","rituximab"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va reported","from":"nct03690388","refs":["thyroid","cabozantinib"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors reported","from":"nct02671435","refs":["metastatic-cancer","monalizumab","durvalumab","cetuximab"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer reported","from":"nct03473743","refs":["urothelial","muscle-invasive-bladder-cancer","erdafitinib","cetrelimab"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer reported","note":"Perioperative durvalumab with neoadjuvant platinum chemotherapy improved event-free survival (hazard ratio 0.69, 95 percent confidence interval 0.55 to 0.88 at the second interim a...","from":"nct03800134","refs":["nsclc","sclc","resectable-nsclc","durvalumab"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer reported","from":"nct03431350","refs":["prostate","prostate-mcrpc","niraparib","cetrelimab"]},{"group":"trial","date":"2023","precision":"year","title":"A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT reported","from":"nct04488822","refs":["tenosynovial-giant-cell-tumour","pexidartinib"]},{"group":"trial","date":"2023","precision":"year","title":"A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Adva...","from":"nct04214288","refs":["breast-hr-positive","camizestrant","fulvestrant"]},{"group":"trial","date":"2023","precision":"year","title":"ADIUVO reported","note":"Five-year recurrence-free survival 79 percent with adjuvant mitotane against 75 percent with surveillance (hazard ratio 0.74, 95% CI 0.30 to 1.85); overall survival not significant...","from":"adiuvo","refs":["localised-adrenocortical-carcinoma","adrenocortical","mitotane"]},{"group":"trial","date":"2023","precision":"year","title":"ADMEC-O (adjuvant nivolumab in completely resected Merkel cell carcinoma) reported","note":"Disease-free survival 85 per cent at 12 months and 84 per cent at 24 months with adjuvant nivolumab against 77 and 73 per cent with observation (hazard ratio 0.58, 95 per cent conf...","from":"admec-o","refs":["merkel-cell-carcinoma","skin-cancer","nivolumab"]},{"group":"trial","date":"2023","precision":"year","title":"ALINA reported","note":"DFS HR 0.24.","from":"alina","refs":["nsclc","alk-positive-nsclc","resectable-nsclc","alectinib"]},{"group":"trial","date":"2023","precision":"year","title":"Alliance A071401 reported","note":"Six-month progression-free survival 83% (10 of 12) in grade 1 and 33% (8 of 24) in grade 2 to 3 NF2-mutant meningioma; both cohorts met the trial's decision criterion for promising...","from":"a071401","refs":["meningioma","gsk2256098"]},{"group":"trial","date":"2023","precision":"year","title":"AMAROS (EORTC 10981-22023) reported","note":"Ten-year axillary recurrence 1.82 percent after radiotherapy against 0.93 percent after clearance, with no difference in survival and lymphoedema halved (11.9 against 24.5 percent...","from":"amaros","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2023","precision":"year","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormo reported","from":"nct04076059","refs":["prostate","prostate-mhspc","enzalutamide"]},{"group":"trial","date":"2023","precision":"year","title":"An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer reported","from":"nct02365597","refs":["urothelial","muscle-invasive-bladder-cancer","erdafitinib"]},{"group":"trial","date":"2023","precision":"year","title":"ANBL17P1 reported","note":"No patient had unacceptable toxicity and none was a feasibility failure over the first five induction cycles with dinutuximab and GM-CSF added.","from":"anbl17p1","refs":["neuroblastoma-high-risk","neuroblastoma","childhood-cancers","dinutuximab"]},{"group":"trial","date":"2023","precision":"year","title":"APACT reported","note":"Independently assessed disease-free survival 19.4 against 18.8 months (hazard ratio 0.88; p 0.18), primary endpoint not met; overall survival 41.8 against 37.7 months at five years...","from":"apact","refs":["pancreatic","resectable-pdac","gemcitabine-nab-paclitaxel","nab-paclitaxel"]},{"group":"trial","date":"2023","precision":"year","title":"ASCOT (JCOG1202) reported","note":"3-year overall survival 77.1% vs 67.6%, adjusted HR 0.69 (0.51 to 0.94), one-sided p=0.0080.","from":"ascot-jcog1202","refs":["gallbladder","cholangiocarcinoma","extrahepatic-cholangiocarcinoma","intrahepatic-cholangiocarcinoma"]},{"group":"trial","date":"2023","precision":"year","title":"Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer reported","from":"nct04590963","refs":["head-and-neck","recurrent-metastatic-hnscc","monalizumab"]},{"group":"trial","date":"2023","precision":"year","title":"Autogene cevumeran phase 1 in resected pancreatic cancer (Memorial Sloan Kettering) reported","note":"Vaccine-induced T cells in 8 of 16 patients; median recurrence-free survival not reached in responders against 13.4 months in non-responders (p 0.003 at 18 months; p 0.007 at 3.2 y...","from":"autogene-cevumeran-phase-1","refs":["pancreatic","resectable-pdac","autogene-cevumeran","atezolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"BEATcc / ENGOT-Cx10 / GOG-3030 reported","note":"OS 32.1 vs 22.8 months (HR 0.68).","from":"beatcc","refs":["cervical","recurrent-metastatic-cervical-cancer","atezolizumab","bevacizumab"]},{"group":"trial","date":"2023","precision":"year","title":"c-TRAK TN reported","note":"ctDNA detected in 27.3% by 12 months; 72% of ctDNA-positive patients had metastases on staging; 0 of 5 patients on pembrolizumab cleared ctDNA.","from":"c-trak-tn","refs":["tnbc","tnbc-early","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"CAIRO5 reported","note":"FOLFOXIRI plus bevacizumab better than a doublet for right-sided or RAS/BRAF-mutant disease; panitumumab no better than bevacizumab for left-sided wild-type disease.","from":"cairo5","refs":["colorectal","folfoxiri","folfox","folfiri"]},{"group":"trial","date":"2023","precision":"year","title":"CALGB 140503 (Alliance) reported","note":"5-year disease-free survival 63.6% (sublobar) vs 64.1% (lobectomy), non-inferior; 5-year overall survival 80.3% vs 78.9%.","from":"calgb-140503","refs":["nsclc","resectable-nsclc"]},{"group":"trial","date":"2023","precision":"year","title":"CALLA reported","note":"Durvalumab added to chemoradiotherapy did not significantly improve progression-free survival in locally advanced cervical cancer.","from":"calla","refs":["locally-advanced-cervical-cancer","cervical","durvalumab","cisplatin"]},{"group":"trial","date":"2023","precision":"year","title":"CanStem111P reported","note":"Median overall survival 11.4 months with napabucasin plus nab-paclitaxel and gemcitabine against 11.7 months with chemotherapy alone (hazard ratio 1.07, 95 percent confidence inter...","from":"canstem111p","refs":["pancreatic","metastatic-pdac","napabucasin","gemcitabine-nab-paclitaxel"]},{"group":"trial","date":"2023","precision":"year","title":"CARES-310 reported","note":"OS 23.8 vs 15.2 months, HR 0.62.","from":"cares-310","refs":["hcc","camrelizumab-rivoceranib"]},{"group":"trial","date":"2023","precision":"year","title":"CARTITUDE-4 reported","note":"PFS HR 0.26; OS HR 0.55.","from":"cartitude-4","refs":["multiple-myeloma","myeloma-relapsed-refractory","ciltacabtagene-autoleucel"]},{"group":"trial","date":"2023","precision":"year","title":"CheckMate 498 reported","note":"OS 13.4 vs 14.9 months, HR 1.31 (95% CI 1.09-1.58); worse with nivolumab.","from":"checkmate-498","refs":["glioblastoma","nivolumab","temozolomide"]},{"group":"trial","date":"2023","precision":"year","title":"CIRCULATE-Japan (GALAXY / VEGA / ALTAIR) reported","note":"GALAXY: ctDNA+ post-op HR for recurrence ~10; ALTAIR: DFS endpoint not met.","from":"circulate-japan","refs":["colorectal","signatera","trifluridine-tipiracil","capox"]},{"group":"trial","date":"2023","precision":"year","title":"CK-301-101 reported","note":"Objective response 47% (37 of 78) in metastatic disease by independent central review at the primary report, median duration of response not reached; the current label reports 50%...","from":"ck-301-101","refs":["cutaneous-scc","advanced-cutaneous-scc","skin-cancer","cosibelimab"]},{"group":"trial","date":"2023","precision":"year","title":"CLL13 / GAIA reported","note":"5-year PFS 81.3% (GIV), 69.8% (GV), 57.4% (RV), 50.7% (CIT).","from":"cll13-gaia","refs":["cll","cll-treatment-naive","venetoclax","obinutuzumab"]},{"group":"trial","date":"2023","precision":"year","title":"CodeBreaK 100 (pancreatic cancer cohort) reported","note":"Objective response 21 percent (8 of 38; 95 percent confidence interval 10 to 37); median progression-free survival 4.0 months; median overall survival 6.9 months; grade 3 treatment...","from":"codebreak-100","refs":["pancreatic","kras-g12c-pdac","metastatic-pdac","sotorasib"]},{"group":"trial","date":"2023","precision":"year","title":"CodeBreaK 300 reported","note":"PFS HR 0.49.","from":"codebreak-300","refs":["colorectal","kras-g12c-colorectal","sotorasib"]},{"group":"trial","date":"2023","precision":"year","title":"COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC reported","from":"nct04068610","refs":["colorectal","durvalumab","oleclumab","folfox"]},{"group":"trial","date":"2023","precision":"year","title":"COMMANDS reported","note":"More patients achieved transfusion independence with a haemoglobin rise on luspatercept than on epoetin alfa; first-line approval in August 2023.","from":"commands","refs":["mds-lower-risk","mds","luspatercept","epoetin-alfa"]},{"group":"trial","date":"2023","precision":"year","title":"CONTACT-03 reported","note":"PFS HR 1.03; OS HR 0.94, negative.","from":"contact-03","refs":["rcc","atezolizumab","cabozantinib"]},{"group":"trial","date":"2023","precision":"year","title":"DESTINY-CRC02 reported","note":"ORR 37.8% (5.4 mg/kg).","from":"destiny-crc02","refs":["colorectal","her2-amplified-colorectal","trastuzumab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"DESTINY-Gastric02 reported","note":"Confirmed durable responses to trastuzumab deruxtecan in a Western population after progression on trastuzumab.","from":"destiny-gastric02","refs":["gastric-her2-positive","gastric","trastuzumab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"DESTINY-Lung02 reported","note":"Confirmed response rate 49.0% (5.4 mg/kg) vs 56.0% (6.4 mg/kg); interstitial lung disease 12.9% vs 28.0%.","from":"destiny-lung02","refs":["nsclc","her2-mutant-nsclc","trastuzumab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"DESTINY-PanTumor02 reported","note":"Endometrial ORR 57.5% (84.6% in IHC 3+); cervical ORR 50%.","from":"destiny-pantumor02","refs":["endometrial","cervical","endometrial-p53-abnormal","uterine-carcinosarcoma"]},{"group":"trial","date":"2023","precision":"year","title":"Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Oper...","from":"nct02003209","refs":["breast-cancer","carboplatin","docetaxel","goserelin"]},{"group":"trial","date":"2023","precision":"year","title":"DUO-E / GOG-3041 / ENGOT-EN10 reported","note":"PFS HR 0.42 (dMMR, durvalumab); 0.57 (pMMR, durvalumab + olaparib).","from":"duo-e","refs":["endometrial","endometrial-mmr-deficient","advanced-recurrent-endometrial-cancer","durvalumab"]},{"group":"trial","date":"2023","precision":"year","title":"DUO-O / ENGOT-ov46 reported","note":"PFS HR 0.63; interim OS HR 0.95.","from":"duo-o","refs":["ovarian","durvalumab","olaparib","bevacizumab"]},{"group":"trial","date":"2023","precision":"year","title":"EMBARK reported","note":"MFS HR 0.42 (combination).","from":"embark","refs":["prostate","prostate-bcr","enzalutamide"]},{"group":"trial","date":"2023","precision":"year","title":"ESPAC-5 reported","note":"One-year overall survival 39 percent with immediate surgery against 78 percent with neoadjuvant gemcitabine plus capecitabine, 84 percent with FOLFIRINOX and 60 percent with chemor...","from":"espac-5","refs":["borderline-resectable-pdac","pancreatic","gemcitabine","capecitabine"]},{"group":"trial","date":"2023","precision":"year","title":"EV-302 / KEYNOTE-A39 reported","note":"OS HR 0.47.","from":"ev-302","refs":["urothelial","muscle-invasive-bladder-cancer","enfortumab-vedotin","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"FIREFLY-1 reported","note":"ORR 67% (RANO-HGG) and 51% (RAPNO-LGG) in arm 1; median DOR 16.6 months.","from":"firefly-1","refs":["paediatric-low-grade-glioma","tovorafenib"]},{"group":"trial","date":"2023","precision":"year","title":"FLAURA2 reported","note":"PFS HR 0.62; OS HR 0.77.","from":"flaura2","refs":["nsclc","egfr-mutant-nsclc","osimertinib"]},{"group":"trial","date":"2023","precision":"year","title":"Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia reported","from":"nct04543279","refs":["primary-myelofibrosis","fostamatinib","ruxolitinib"]},{"group":"trial","date":"2023","precision":"year","title":"FOxTROT reported","note":"Residual or recurrent disease within two years 16.9 percent with six weeks of preoperative chemotherapy against 21.5 percent with postoperative chemotherapy alone (rate ratio 0.72...","from":"foxtrot","refs":["colorectal","colon-cancer","folfox","capox"]},{"group":"trial","date":"2023","precision":"year","title":"FRESCO-2 reported","note":"OS 7.4 vs 4.8 months, HR 0.66.","from":"fresco-2","refs":["colorectal","fruquintinib"]},{"group":"trial","date":"2023","precision":"year","title":"GD2-CART01 (Bambino Gesù phase 1/2) reported","note":"ORR 63%, CR 33%; 3-year OS 60%.","from":"gd2-cart01","refs":["neuroblastoma","neuroblastoma-high-risk"]},{"group":"trial","date":"2023","precision":"year","title":"HBI0101 (NXC-201) multiple myeloma phase 1 reported","note":"Overall response rate 75%, (stringent) complete response 50% and very good partial response 25% in the first 20 patients; grade 1 to 2 cytokine release syndrome in 90%, no grade 3...","from":"nxc-201-mm","refs":["multiple-myeloma","nxc-201-car-t"]},{"group":"trial","date":"2023","precision":"year","title":"HER2CLIMB-02 reported","note":"PFS 9.5 vs 7.4 months, HR 0.76; OS no benefit.","from":"her2climb-02","refs":["breast-her2-positive","her2-positive-breast-brain-metastases","tucatinib","trastuzumab-emtansine"]},{"group":"trial","date":"2023","precision":"year","title":"HERIZON-BTC-01 reported","note":"Confirmed ORR by independent central review 41.3% (33/80, 95% CI 30.4 to 52.8) in HER2 IHC 2+/3+ cohort; grade 3 treatment-related adverse events 18%; 53% of patients had gallbladd...","from":"herizon-btc-01","refs":["gallbladder","cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma"]},{"group":"trial","date":"2023","precision":"year","title":"IMAGINE (varnimcabtagene autoleucel, Immuneel) reported","from":"imagine-varnimcabtagene","refs":["dlbcl","all-leukemia","varnimcabtagene-autoleucel"]},{"group":"trial","date":"2023","precision":"year","title":"IMbrave050 reported","note":"Interim RFS HR 0.72; benefit not sustained at update.","from":"imbrave050","refs":["hcc","hcc-early","atezolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"IMerge reported","note":"Imetelstat produced eight-week transfusion independence in significantly more patients than placebo; approved in June 2024.","from":"imerge","refs":["mds-lower-risk","mds","imetelstat"]},{"group":"trial","date":"2023","precision":"year","title":"INAVO120 reported","note":"PFS 15.0 vs 7.3 months, HR 0.43; OS 34.0 vs 27.0 months, HR 0.67.","from":"inavo120","refs":["breast-hr-positive","hr-positive-metastatic-post-cdk46","inavolisib","palbociclib"]},{"group":"trial","date":"2023","precision":"year","title":"IND.227 / KEYNOTE-483 reported","note":"OS 17.3 vs 16.1 months, HR 0.79; ORR 52% vs 29%.","from":"keynote-483","refs":["mesothelioma","pleural-mesothelioma","pembrolizumab","pemetrexed"]},{"group":"trial","date":"2023","precision":"year","title":"INDIGO reported","note":"PFS 27.7 vs 11.1 months, HR 0.39.","from":"indigo","refs":["glioblastoma","idh-mutant-astrocytoma","oligodendroglioma","vorasidenib"]},{"group":"trial","date":"2023","precision":"year","title":"innovaTV 301 / ENGOT-cx12 / GOG-3057 reported","note":"OS 11.5 vs 9.5 months (HR 0.70).","from":"innovatv-301","refs":["cervical","recurrent-metastatic-cervical-cancer","tisotumab-vedotin"]},{"group":"trial","date":"2023","precision":"year","title":"INSITE reported","note":"Residual cancer removed by guided margins in 27 of 357 patients; per-margin specificity 85.2% and sensitivity 49.3%; second surgery avoided in 9 of 62 patients with positive margin...","from":"insite","refs":["breast-hr-positive","tnbc","breast-her2-positive","pegulicianine"]},{"group":"trial","date":"2023","precision":"year","title":"INTERLACE reported","note":"5-year OS 80% vs 72% (HR 0.60); PFS HR 0.65.","from":"interlace","refs":["cervical","locally-advanced-cervical-cancer","carboplatin","paclitaxel"]},{"group":"trial","date":"2023","precision":"year","title":"KarMMa-3 reported","note":"PFS 13.3 vs 4.4 months, HR 0.49.","from":"karmma-3","refs":["multiple-myeloma","myeloma-relapsed-refractory","idecabtagene-vicleucel"]},{"group":"trial","date":"2023","precision":"year","title":"KEYNOTE-671 reported","note":"EFS HR 0.58; OS HR 0.72.","from":"keynote-671","refs":["nsclc","resectable-nsclc","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"KEYNOTE-859 reported","note":"OS HR 0.78 (all); CPS ≥10 OS 15.7 vs 11.8 months (HR 0.65).","from":"keynote-859","refs":["gastric","gastric-pdl1-high","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"KEYNOTE-966 reported","note":"OS 12.7 vs 10.9 months, HR 0.83.","from":"keynote-966","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","gallbladder"]},{"group":"trial","date":"2023","precision":"year","title":"KEYNOTE-A18 / ENGOT-cx11 / GOG-3047 reported","note":"PFS HR 0.70; 36-month OS 82.6% vs 74.8% (HR 0.67).","from":"keynote-a18","refs":["cervical","locally-advanced-cervical-cancer","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"LIBRETTO-431 reported","note":"PFS HR 0.46.","from":"libretto-431","refs":["nsclc","ret-fusion-nsclc","selpercatinib"]},{"group":"trial","date":"2023","precision":"year","title":"LIBRETTO-531 reported","note":"PFS HR 0.28; 12-month PFS 86.8% vs 65.7%.","from":"libretto-531","refs":["thyroid","selpercatinib"]},{"group":"trial","date":"2023","precision":"year","title":"LITESPARK-005 reported","note":"PFS HR 0.75; ORR 22.7% vs 3.5%; OS not significant.","from":"litespark-005","refs":["rcc","belzutifan","everolimus"]},{"group":"trial","date":"2023","precision":"year","title":"Low-dose nivolumab plus metronomic chemotherapy (Tata Memorial) reported","note":"1-year OS 43.4% vs 16.3%; median OS 10.1 vs 6.7 months; HR 0.545.","from":"low-dose-nivolumab-tmh","refs":["head-and-neck","recurrent-metastatic-hnscc","buccal-mucosa-cancer","nivolumab"]},{"group":"trial","date":"2023","precision":"year","title":"Low-dose olanzapine for cancer anorexia (Tata Memorial) reported","note":"Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.","from":"olanzapine-appetite-tmh","refs":["gastric","nsclc","pancreatic","hcc"]},{"group":"trial","date":"2023","precision":"year","title":"LUMINA reported","note":"5-year local recurrence 2.3% without radiotherapy in luminal A disease.","from":"lumina","refs":["breast-hr-positive","breast-cancer"]},{"group":"trial","date":"2023","precision":"year","title":"MagnetisMM-3 reported","note":"ORR 61%.","from":"magnetismm-3","refs":["multiple-myeloma","myeloma-relapsed-refractory","elranatamab"]},{"group":"trial","date":"2023","precision":"year","title":"MAJIC-PV reported","note":"Complete response within 1 year: 43% vs 26%; complete response associated with better event-free survival.","from":"majic-pv","refs":["polycythaemia-vera","ruxolitinib"]},{"group":"trial","date":"2023","precision":"year","title":"MARIPOSA reported","note":"PFS HR 0.70; OS HR 0.75.","from":"mariposa","refs":["nsclc","egfr-mutant-nsclc","amivantamab"]},{"group":"trial","date":"2023","precision":"year","title":"MASAI (Mammography Screening with Artificial Intelligence) reported","note":"Cancer detection 6.1 vs 5.1 per 1,000; screen-reading workload reduced 44.3% (interim).","from":"masai","refs":["breast-hr-positive","tnbc","transpara"]},{"group":"trial","date":"2023","precision":"year","title":"MIMic-01: healthy-donor FMT plus anti-PD-1, first-line melanoma reported","note":"ORR 65% (13 of 20), 4 complete responses; no FMT-related serious adverse events.","from":"mimic-01","refs":["melanoma","nivolumab","pembrolizumab"]},{"group":"trial","date":"2023","precision":"year","title":"MIRASOL / GOG-3045 reported","note":"OS 16.46 vs 12.75 months (HR 0.67).","from":"mirasol","refs":["ovarian","platinum-resistant-ovarian-cancer","mirvetuximab-soravtansine"]},{"group":"trial","date":"2023","precision":"year","title":"MOMENTUM reported","note":"Momelotinib improved symptom response, transfusion independence and spleen response compared with danazol; approved in September 2023.","from":"momentum","refs":["primary-myelofibrosis","myeloproliferative-neoplasms","momelotinib","danazol"]},{"group":"trial","date":"2023","precision":"year","title":"NAPOLI 3 reported","note":"OS HR 0.84; PFS HR 0.69.","from":"napoli-3","refs":["pancreatic","metastatic-pdac","nalirifox","gemcitabine-nab-paclitaxel"]},{"group":"trial","date":"2023","precision":"year","title":"NATALEE reported","note":"iDFS HR 0.75.","from":"natalee","refs":["breast-hr-positive","hr-positive-early-high-risk","ribociclib"]},{"group":"trial","date":"2023","precision":"year","title":"NEONAX reported","note":"18-month disease-free survival 33.3 percent (perioperative) and 41.4 percent (adjuvant), both below the 55 percent target; median overall survival 25.5 against 16.7 months in the i...","from":"neonax","refs":["pancreatic","resectable-pdac","gemcitabine-nab-paclitaxel"]},{"group":"trial","date":"2023","precision":"year","title":"NMTRC003/003B (DFMO maintenance) reported","note":"EFS HR 0.48 vs external control.","from":"nmtrc003","refs":["neuroblastoma","neuroblastoma-high-risk","eflornithine"]},{"group":"trial","date":"2023","precision":"year","title":"NOTABLE (nimotuzumab, KRAS wild-type pancreatic cancer) reported","note":"Overall survival improved with nimotuzumab plus gemcitabine in KRAS wild-type disease.","from":"notable-trial","refs":["pancreatic","kras-wild-type-pdac","nimotuzumab","gemcitabine"]},{"group":"trial","date":"2023","precision":"year","title":"NRG-GY018 / KEYNOTE-868 reported","note":"PFS HR 0.30 (dMMR), 0.54 (pMMR).","from":"nrg-gy018-keynote-868","refs":["endometrial","endometrial-mmr-deficient","advanced-recurrent-endometrial-cancer","endometrial-nsmp"]},{"group":"trial","date":"2023","precision":"year","title":"ORIENT-16 reported","note":"OS 15.2 vs 12.3 months (HR 0.77); CPS ≥5: 18.4 vs 12.9 months (HR 0.66).","from":"orient-16","refs":["gastric","sintilimab","oxaliplatin"]},{"group":"trial","date":"2023","precision":"year","title":"Peritumoral lidocaine before breast cancer surgery (Tata Memorial) reported","note":"5-year DFS 86.6% vs 82.6% (HR 0.74); OS 90.1% vs 86.4% (HR 0.71).","from":"lidocaine-peritumoral-tmh","refs":["breast-hr-positive","tnbc","breast-her2-positive"]},{"group":"trial","date":"2023","precision":"year","title":"PERSEUS reported","note":"PFS HR 0.42; 48-month PFS 84.3% vs 67.7%.","from":"perseus","refs":["multiple-myeloma","myeloma-transplant-eligible","daratumumab","bortezomib"]},{"group":"trial","date":"2023","precision":"year","title":"PHAROS reported","note":"Response rate 75% (treatment-naive, n=59) and 46% (previously treated, n=39); FDA approval October 2023.","from":"pharos","refs":["nsclc","braf-v600e-nsclc","encorafenib","binimetinib"]},{"group":"trial","date":"2023","precision":"year","title":"Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 reported","note":"Pancreatic cancer cohort: objective response in 7 of 21 patients (33.3 percent); across the 57 evaluable non-lung, non-colorectal KRAS G12C tumours response 35.1 percent, median du...","from":"nct03785249","refs":["metastatic-cancer","colorectal","kras-g12c-colorectal","kras-g12c-pdac"]},{"group":"trial","date":"2023","precision":"year","title":"Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia reported","from":"nct01772420","refs":["leukaemia","eltrombopag","lenalidomide"]},{"group":"trial","date":"2023","precision":"year","title":"PREHAB: multimodal prehabilitation before colorectal cancer surgery reported","note":"Fewer severe complications and faster recovery with prehabilitation; surgery not delayed.","from":"prehab-trial","refs":["colorectal"]},{"group":"trial","date":"2023","precision":"year","title":"PROSPECT (Alliance N1048) reported","note":"5-year disease-free survival 80.8% (FOLFOX, selective chemoradiation) vs 78.6% (chemoradiation), non-inferior; 9% of the FOLFOX arm received chemoradiation.","from":"prospect","refs":["colorectal","rectal-cancer","folfox","fluorouracil"]},{"group":"trial","date":"2023","precision":"year","title":"PSMAfore reported","note":"rPFS HR 0.41.","from":"psmafore","refs":["prostate","prostate-mcrpc","pluvicto"]},{"group":"trial","date":"2023","precision":"year","title":"RUBY / ENGOT-EN6 / GOG-3031 reported","note":"OS 44.6 vs 28.2 months overall (HR 0.69); dMMR PFS HR 0.28.","from":"ruby","refs":["endometrial","endometrial-mmr-deficient","advanced-recurrent-endometrial-cancer","uterine-carcinosarcoma"]},{"group":"trial","date":"2023","precision":"year","title":"SANO reported","note":"2-year OS non-inferior (HR 1.14); ~one-third avoided surgery.","from":"sano","refs":["esophageal"]},{"group":"trial","date":"2023","precision":"year","title":"ScreenTrustCAD reported","note":"One radiologist plus AI detected 261 screen-detected cancers vs 250 for two radiologists (relative proportion 1.04, 95% CI 1.00 to 1.09), meeting non-inferiority; AI alone 246 and...","from":"screentrustcad","refs":["breast-hr-positive","tnbc","lunit-insight-mmg"]},{"group":"trial","date":"2023","precision":"year","title":"Serial FES PET/CT to Measure Hormone Expression in Patients Undergoing Endocrine Targeted Therapy reported","from":"nct04692103","refs":["breast-cancer","fluoroestradiol-f18","fludeoxyglucose-f18"]},{"group":"trial","date":"2023","precision":"year","title":"SOUND (Sentinel Node vs Observation After Axillary Ultra-Sound) reported","note":"Five-year distant disease-free survival 98.0 percent without axillary surgery against 97.7 percent with sentinel node biopsy (hazard ratio 0.84, non-inferiority p=0.02).","from":"sound","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2023","precision":"year","title":"SPOTLIGHT & GLOW reported","note":"SPOTLIGHT OS 18.2 vs 15.5 months; GLOW OS 14.4 vs 12.2 months.","from":"spotlight-glow","refs":["gastric","gastric-cldn18-2-positive","zolbetuximab","folfox"]},{"group":"trial","date":"2023","precision":"year","title":"Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) reported","from":"nct03003962","refs":["nsclc","pdl1-high-nsclc","durvalumab","carboplatin"]},{"group":"trial","date":"2023","precision":"year","title":"Study of Melflufen (Melphalan Flufenamide) in Combination With Daratumumab in Relapsed-Refractory Multiple Myeloma reported","from":"nct04649060","refs":["multiple-myeloma","melflufen","dexamethasone","daratumumab"]},{"group":"trial","date":"2023","precision":"year","title":"Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple reported","from":"nct04162210","refs":["multiple-myeloma","myeloma-relapsed-refractory","belantamab-mafodotin"]},{"group":"trial","date":"2023","precision":"year","title":"Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostate Cancer reported","from":"nct03315754","refs":["prostate","padeliporfin"]},{"group":"trial","date":"2023","precision":"year","title":"SUNLIGHT reported","note":"OS 10.8 vs 7.5 months, HR 0.61.","from":"sunlight","refs":["colorectal","trifluridine-tipiracil","bevacizumab"]},{"group":"trial","date":"2023","precision":"year","title":"SWOG S1826 reported","note":"2-year PFS 92% vs 83%, HR 0.45.","from":"swog-s1826","refs":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","nivolumab","brentuximab-vedotin"]},{"group":"trial","date":"2023","precision":"year","title":"SYD985 vs. Physician's Choice in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer reported","from":"nct03262935","refs":["breast-cancer","trastuzumab-duocarmazine","lapatinib","capecitabine"]},{"group":"trial","date":"2023","precision":"year","title":"TADPOLE (CDRB436G2201) reported","note":"ORR 47% vs 11%; median PFS 20.1 vs 7.4 months, HR 0.31.","from":"tadpole","refs":["paediatric-low-grade-glioma","dabrafenib-trametinib","carboplatin","vincristine"]},{"group":"trial","date":"2023","precision":"year","title":"TALAPRO-2 reported","note":"rPFS HR 0.63 (ITT); OS HR 0.80 (ITT), 0.62 (HRR-mutant).","from":"talapro-2","refs":["prostate","prostate-mcrpc","talazoparib","enzalutamide"]},{"group":"trial","date":"2023","precision":"year","title":"Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARC...","from":"nct03213665","refs":["sarcoma","tazemetostat"]},{"group":"trial","date":"2023","precision":"year","title":"THOR reported","note":"OS 12.1 vs 7.8 months, HR 0.64 (cohort 1).","from":"thor","refs":["urothelial","erdafitinib"]},{"group":"trial","date":"2023","precision":"year","title":"TRACERx reported","note":"Copy-number heterogeneity predicted recurrence or death with a hazard ratio of 4.9; 8 percent of adenocarcinomas in people with a smoking history carried no tobacco signature; in t...","from":"tracerx","refs":["nsclc","lung-cancer","lung-adenocarcinoma"]},{"group":"trial","date":"2023","precision":"year","title":"TRANSCEND CLL 004 reported","note":"CR/CRi 18-20%; ORR 47%; uMRD blood 64%.","from":"transcend-cll-004","refs":["cll","cll-relapsed","lisocabtagene-maraleucel"]},{"group":"trial","date":"2023","precision":"year","title":"TRITON3 reported","note":"Median imaging-based progression-free survival 11.2 against 6.4 months in the BRCA subgroup (hazard ratio 0.50, 95 percent confidence interval 0.36 to 0.69) and 10.2 against 6.4 mo...","from":"triton3","refs":["prostate","prostate-mcrpc","rucaparib"]},{"group":"trial","date":"2023","precision":"year","title":"TROPION-Breast01 reported","note":"PFS HR 0.63; OS HR 1.01.","from":"tropion-breast01","refs":["breast-hr-positive","datopotamab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"TROPION-Lung01 reported","note":"PFS HR 0.75; OS HR 0.94.","from":"tropion-lung01","refs":["nsclc","pdl1-high-nsclc","datopotamab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"TROPION-Lung05 reported","note":"ORR 43.6% in EGFR-mutant disease.","from":"tropion-lung05","refs":["nsclc","egfr-mutant-nsclc","datopotamab-deruxtecan"]},{"group":"trial","date":"2023","precision":"year","title":"Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer reported","from":"nct04373369","refs":["extensive-stage-sclc","vorolanib","atezolizumab"]},{"group":"guideline","date":"2023-01","precision":"month","title":"ESMO ESMO CPG metastatic colorectal cancer 2023 (Cervantes et al.) for Colorectal cancer","note":"1 row added, 1 row recategorised. Anchored to Annals of Oncology publication, January 2023.","from":"colorectal","refs":["tucatinib","trastuzumab","mountaineer","panitumumab"]},{"group":"regulatory","date":"2023-01","precision":"month","title":"FAP-2286 (177Lu / 68Ga): filing (US)","note":"Novartis acquires rights after Clovis bankruptcy","from":"fap-2286","refs":[]},{"group":"regulatory","date":"2023-01","precision":"month","title":"Zanidatamab: designation (US)","note":"Breakthrough Therapy designation, HER2+ biliary tract cancer","from":"zanidatamab","refs":[]},{"group":"regulatory","date":"2023-01-19","precision":"day","title":"Tucatinib: approval (US)","note":"HER2+ RAS wild-type metastatic colorectal cancer with trastuzumab (MOUNTAINEER, accelerated)","from":"tucatinib","refs":[]},{"group":"regulatory","date":"2023-01-19","precision":"day","title":"Zanubrutinib: approval (US)","note":"CLL/SLL","from":"zanubrutinib","refs":[]},{"group":"regulatory","date":"2023-01-27","precision":"day","title":"Elacestrant: approval (US)","note":"ESR1-mutated ER+/HER2- advanced breast cancer after ≥1 endocrine therapy (EMERALD): first oral SERD","from":"elacestrant","refs":[]},{"group":"regulatory","date":"2023-02","precision":"month","title":"Sonesitatug vedotin: filing (US)","note":"AstraZeneca licenses global rights from KYM Biosciences","from":"cmg901","refs":[]},{"group":"regulatory","date":"2023-02-03","precision":"day","title":"Sacituzumab govitecan: approval (US)","note":"HR+/HER2- metastatic breast cancer after endocrine therapy and ≥2 chemotherapies (TROPiCS-02)","from":"sacituzumab-govitecan","refs":[]},{"group":"regulatory","date":"2023-02-22","precision":"day","title":"Intismeran autogene: designation (US)","note":"Breakthrough Therapy designation, adjuvant melanoma","from":"intismeran-autogene","refs":[]},{"group":"guideline","date":"2023-03","precision":"month","title":"NCCN 2023 update for Melanoma","note":"1 row recategorised. Anchored to DREAMseq publication (JCO, January 2023).","from":"melanoma","refs":["dabrafenib-trametinib","nivolumab","ipilimumab","dreamseq"]},{"group":"regulatory","date":"2023-03","precision":"month","title":"Vorasidenib: designation (US)","note":"Breakthrough Therapy designation","from":"vorasidenib","refs":[]},{"group":"regulatory","date":"2023-03-03","precision":"day","title":"Abemaciclib: label change (US)","note":"Adjuvant indication broadened to remove Ki-67 requirement","from":"abemaciclib","refs":[]},{"group":"guideline","date":"2023-04","precision":"month","title":"ESMO ESMO CPG oncogene-addicted metastatic NSCLC 2023 (Hendriks et al.) for Non-small-cell lung cancer","note":"2 rows added. Anchored to Annals of Oncology publication, 2023.","from":"nsclc","refs":["lorlatinib","alectinib","brigatinib","crizotinib"]},{"group":"regulatory","date":"2023-04","precision":"month","title":"Intismeran autogene: designation (EU)","note":"PRIME designation","from":"intismeran-autogene","refs":[]},{"group":"regulatory","date":"2023-04-03","precision":"day","title":"Enfortumab vedotin: approval (US)","note":"Accelerated approval with pembrolizumab, cisplatin-ineligible first line","from":"enfortumab-vedotin","refs":[]},{"group":"regulatory","date":"2023-04-06","precision":"day","title":"Ibrutinib: withdrawal (US)","note":"MCL and MZL indications voluntarily withdrawn after confirmatory trials missed","from":"ibrutinib","refs":[]},{"group":"regulatory","date":"2023-04-19","precision":"day","title":"Polatuzumab vedotin: approval (US)","note":"Frontline Pola-R-CHP (POLARIX)","from":"polatuzumab-vedotin","refs":[]},{"group":"regulatory","date":"2023-05","precision":"month","title":"Lifileucel: filing (US)","note":"BLA submitted","from":"lifileucel","refs":[]},{"group":"regulatory","date":"2023-05-19","precision":"day","title":"Epcoritamab: approval (US)","note":"Accelerated approval in DLBCL (EPCORE NHL-1)","from":"epcoritamab","refs":[]},{"group":"regulatory","date":"2023-05-31","precision":"day","title":"Olaparib: approval (US)","note":"With abiraterone in BRCA-mutated mCRPC (PROpel)","from":"olaparib","refs":[]},{"group":"guideline","date":"2023-06","precision":"month","title":"NCCN 2023 updates for Diffuse large B-cell lymphoma","note":"2 rows added. Anchored to FDA approvals of polatuzumab-R-CHP in the first line (April 2023, POLARIX), epcoritamab (May 2023) and glofitamab (June 2023).","from":"dlbcl","refs":["polatuzumab-vedotin","polarix","epcoritamab","glofitamab"]},{"group":"guideline","date":"2023-06","precision":"month","title":"NCCN 2023 updates for Prostate cancer","note":"1 row added. Anchored to FDA approvals of olaparib with abiraterone (May 2023, PROpel) and talazoparib with enzalutamide (June 2023, TALAPRO-2) for HRR-mutated castration-resistant...","from":"prostate","refs":["olaparib","talazoparib","abiraterone","enzalutamide"]},{"group":"regulatory","date":"2023-06-15","precision":"day","title":"Glofitamab: approval (US)","note":"Accelerated approval, relapsed/refractory DLBCL after ≥2 lines","from":"glofitamab","refs":[]},{"group":"regulatory","date":"2023-06-20","precision":"day","title":"Talazoparib: approval (US)","note":"HRR-mutant mCRPC with enzalutamide (TALAPRO-2)","from":"talazoparib","refs":[]},{"group":"guideline","date":"2023-07","precision":"month","title":"NCCN 2023 update for Acute myeloid leukaemia","note":"1 row added. Anchored to FDA approval of quizartinib with induction and consolidation for FLT3-ITD AML, July 2023 (QuANTUM-First).","from":"aml","refs":["quizartinib","midostaurin","quantum-first"]},{"group":"regulatory","date":"2023-07","precision":"month","title":"Glofitamab: approval (EU)","note":"Conditional marketing authorisation","from":"glofitamab","refs":[]},{"group":"regulatory","date":"2023-07-20","precision":"day","title":"Quizartinib: approval (US)","note":"Frontline FLT3-ITD AML (QuANTUM-First)","from":"quizartinib","refs":[]},{"group":"regulatory","date":"2023-07-31","precision":"day","title":"Dostarlimab: approval (US)","note":"dMMR primary advanced/recurrent endometrial cancer with chemotherapy (RUBY)","from":"dostarlimab","refs":[]},{"group":"guideline","date":"2023-08","precision":"month","title":"NCCN 2021-2023 updates for Multiple myeloma","note":"1 row added, 1 row removed. Anchored to FDA approvals of idecabtagene vicleucel (March 2021), ciltacabtagene autoleucel (February 2022), teclistamab (October 2022), talquetamab and...","from":"multiple-myeloma","refs":["idecabtagene-vicleucel","ciltacabtagene-autoleucel","teclistamab","elranatamab"]},{"group":"regulatory","date":"2023-08","precision":"month","title":"Bevacizumab: label change (US)","note":"With trifluridine/tipiracil in refractory mCRC","from":"bevacizumab","refs":[]},{"group":"regulatory","date":"2023-08","precision":"month","title":"Trifluridine/tipiracil: approval (US)","note":"SUNLIGHT combination","from":"trifluridine-tipiracil","refs":[]},{"group":"regulatory","date":"2023-08-11","precision":"day","title":"Niraparib: approval (US)","note":"Niraparib + abiraterone (Akeega) for BRCA-mutated mCRPC (MAGNITUDE)","from":"niraparib","refs":[]},{"group":"expected","date":"2023-08-31","precision":"day","title":"Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer: primary...","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct04665856","refs":[]},{"group":"regulatory","date":"2023-09","precision":"month","title":"Elacestrant: approval (EU)","note":"EMA approval","from":"elacestrant","refs":[]},{"group":"guideline","date":"2023-10","precision":"month","title":"ESMO ESMO-ESGO consensus and CPG newly diagnosed and relapsed epithelial ovarian cancer 2023 for Ovarian cancer","note":"1 row added, 1 row recategorised. Anchored to Annals of Oncology publication, 2023.","from":"ovarian","refs":["olaparib","niraparib","paola-1","prima"]},{"group":"guideline","date":"2023-10","precision":"month","title":"NCCN 2022-2023 updates for Non-small-cell lung cancer","note":"2 rows added. Anchored to FDA approvals of neoadjuvant nivolumab with chemotherapy (March 2022, CheckMate 816) and perioperative pembrolizumab (October 2023, KEYNOTE-671).","from":"nsclc","refs":["nivolumab","checkmate-816","pembrolizumab","keynote-671"]},{"group":"regulatory","date":"2023-10-11","precision":"day","title":"Encorafenib: approval (US)","note":"BRAF V600E NSCLC with binimetinib","from":"encorafenib","refs":[]},{"group":"regulatory","date":"2023-10-16","precision":"day","title":"Pembrolizumab: approval (US)","note":"Perioperative NSCLC (KEYNOTE-671)","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2023-10-27","precision":"day","title":"Toripalimab: approval (US)","note":"First FDA approval for nasopharyngeal carcinoma","from":"toripalimab","refs":[]},{"group":"guideline","date":"2023-11","precision":"month","title":"NCCN 2023 updates for Colorectal cancer","note":"1 row recategorised, 1 row added. Anchored to FDA approvals of trifluridine/tipiracil with bevacizumab (August 2023, SUNLIGHT) and fruquintinib (November 2023, FRESCO-2).","from":"colorectal","refs":["trifluridine-tipiracil","bevacizumab","sunlight","fruquintinib"]},{"group":"guideline","date":"2023-11","precision":"month","title":"NCCN 2023 updates for HR-positive / HER2-negative breast cancer","note":"2 rows added. Anchored to FDA approvals of elacestrant (January 2023) and capivasertib (November 2023).","from":"breast-hr-positive","refs":["elacestrant","emerald","capivasertib","capitello-291"]},{"group":"regulatory","date":"2023-11","precision":"month","title":"Vusolimogene oderparepvec: designation (US)","note":"Breakthrough Therapy designation, anti-PD-1-failed melanoma","from":"vusolimogene-oderparepvec","refs":[]},{"group":"regulatory","date":"2023-11-08","precision":"day","title":"Fruquintinib: approval (US)","note":"FRESCO-2","from":"fruquintinib","refs":[]},{"group":"regulatory","date":"2023-11-16","precision":"day","title":"Capivasertib: approval (US)","note":"HR+/HER2- breast cancer with PIK3CA/AKT1/PTEN alteration, with fulvestrant (CAPItello-291): first AKT inhibitor","from":"capivasertib","refs":[]},{"group":"regulatory","date":"2023-11-27","precision":"day","title":"Nirogacestat: approval (US)","note":"First systemic therapy for desmoid tumours (DeFi)","from":"nirogacestat","refs":[]},{"group":"guideline","date":"2023-12","precision":"month","title":"NCCN 2022-2023 updates for Chronic lymphocytic leukaemia","note":"1 row recategorised, 1 row added, 1 row removed. Anchored to FDA approval of zanubrutinib for CLL (January 2023, ALPINE and SEQUOIA) and pirtobrutinib after BTK and BCL-2 inhibitor...","from":"cll","refs":["zanubrutinib","acalabrutinib","ibrutinib","alpine"]},{"group":"guideline","date":"2023-12","precision":"month","title":"NCCN 2023 update for Renal cell carcinoma","note":"1 row added. Anchored to FDA approval of belzutifan after immunotherapy and VEGF-TKI, December 2023 (LITESPARK-005).","from":"rcc","refs":["belzutifan","litespark-005"]},{"group":"regulatory","date":"2023-12","precision":"month","title":"Cosibelimab: complete response letter (US)","note":"Complete response letter citing third-party manufacturing inspection findings","from":"cosibelimab","refs":[]},{"group":"regulatory","date":"2023-12","precision":"month","title":"Patritumab deruxtecan: filing (US)","note":"BLA submitted (HERTHENA-Lung01)","from":"patritumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2023-12","precision":"month","title":"Sotorasib: complete response letter (US)","note":"FDA declines full approval based on CodeBreaK 200; postmarketing dose study required","from":"sotorasib","refs":[]},{"group":"regulatory","date":"2023-12-01","precision":"day","title":"Pirtobrutinib: approval (US)","note":"CLL/SLL accelerated approval","from":"pirtobrutinib","refs":[]},{"group":"regulatory","date":"2023-12-11","precision":"day","title":"Izalontamab brengitecan: filing (US)","note":"BMS licenses global rights ex-China from SystImmune (up to $8.4B)","from":"izalontamab-brengitecan","refs":[]},{"group":"regulatory","date":"2023-12-13","precision":"day","title":"Eflornithine (DFMO): approval (US)","note":"First oral maintenance therapy; externally controlled evidence","from":"eflornithine","refs":[]},{"group":"regulatory","date":"2023-12-14","precision":"day","title":"Belzutifan: approval (US)","note":"Advanced RCC after PD-1/PD-L1 and VEGF-TKI (LITESPARK-005)","from":"belzutifan","refs":[]},{"group":"regulatory","date":"2023-12-15","precision":"day","title":"Enfortumab vedotin: approval (US)","note":"Full approval with pembrolizumab, all first-line advanced urothelial cancer (EV-302)","from":"enfortumab-vedotin","refs":[]},{"group":"expected","date":"2023-12-25","precision":"day","title":"A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutat...","note":"Actual primary completion date on ClinicalTrials.gov.","from":"nct03182244","refs":[]}]},"route":"/years/2023/","neighbours":{"year":[{"id":"2022","kind":"year","name":"2022 in oncology","route":"/years/2022/"},{"id":"2024","kind":"year","name":"2024 in oncology","route":"/years/2024/"}]}}